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Abstract of the Dissertation
Drug Repurposing Using the Anthrax Toxin Internalization Pathway
By
Leeor Zilbermintz
Keck Graduate Institute of Applied Life Sciences: 2017
Pathogens and pathogenic agents such as lethal toxin, exploit host proteins for their success.
Antibiotic discovery efforts have been focused on developing drugs that selectively target pathogens, despite
the potential for drug resistance and providing no guarantee of fewer side effects for the patient. This
dissertation describes the systematic efforts to identify drugs that alter those host proteins that are involved
in the anthrax toxin internalization pathway. Anthrax is a rare and lethal disease caused by the toxin
producing, gram-positive bacterium, Bacillus anthracis. The lethality of anthrax is largely attributed to the
toxins that circulate within the host, destroying host tissues as well as the immune system, thus hampering
host efforts to destroy the bacteria. Drug candidates were identified through cellular and protein-based
screens using a drug library comprised of previously approved and off-patent drugs. Such a library creates
the potential for identifying therapies for new indications, while potentially reducing the time and capital
necessary for regulatory approval. We have successfully identified an anthrax antitoxin drug that interferes
with host Cathepsin B, a lysosomal protein necessary for authophagic flux. On the observation that Cathepsin
B is necessary for the success of other pathogenic agents, we demonstrated that our drug hit could prevent
other infections, such as Ebola. Subsequent screens were designed to optimize the search for broad-spectrum
therapies that interfere with those host proteins involved in the anthrax toxin internalization pathway but
which play a role in internalizing other pathogenic agents such as Pseudomonas exotoxin A, Cholera, and
Diphtheria toxin. We were able to identify a drug that inhibits host caspases, proteases involved in
programmed cell death, and showed that this drug was a successful broad-spectrum therapy for Zika virus.
Finally we aimed to indentify drugs that could simultaneously interfere with host proteins and anthrax lethal
toxin, and identified two drugs. Drug optimization and drug combinations based on our host-oriented and
broad-spectrum identification methods could provide for more effective and better-tolerated therapies for
patients suffering from infectious diseases.
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Preface

It is not the most intellectual of the species that survives; it is not the strongest
that survives; but the species that survives is the one that is able best to adapt and
adjust to the changing environment in which it finds itself.
-Paraphrased by Leon C. Megginson from Charles Darwin’s “On the Origin of Species”(1963)
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Chapter 1
The Pre Antibiotic Era
Antimicrobials are not only one of the most successful forms of chemotherapy, or
treating diseases with chemical substances, but they are arguably one of the most important
medical advances in human history. In 1941, during the Second World War, Selman Waksman
coined the word antibiotic to describe a small molecule made from a microorganism that is
intended to prohibit the growth of other microbes [1]. Penicillin, which was being manufactured
at high quantities during this time, and was discovered from a mold, is considered to be one of
the first antibiotics in the “antibiotic era [2].”
Antibiotic use by humans, whether purposeful or by accident, can be traced back to
ancient civilizations. For example, Tetracycline, which is produced by the genus Streptomyces,
and is known to aggregate in the calcium of bones, was identified in the remains of the ancient
Nubian people who died around 350-550 CE. It is hypothesized that the conditions in which
these people stored grains for beer were ideal for a Streptomyces contamination. Mass
spectrometry of these bones indicates the presence of Tetracyclines in the Nubian diet.
Histological studies of femoral mid shafts from Roman skeletons from the Dakhleh Oasis in
Egypt, also exhibit tetracycline in the diet as evidenced by discrete fluorochrome labeling [3].
The Nubian people had less evidence of bone infections and infections in general. Nowadays
people still use Tetracycline for a wide range of antibiotic infections and those who have taken it
at a young age, often have visible stains on their teeth as a result. There is still no consensus
whether these ancient people realized the antibiotic properties of their beer [3].
Since Tetracycline binds to bone, there is a physical marker of antibiotic use. However,
other antibiotics do not leave behind much evidence and their use can only be attributed to
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ancient customs and practices left behind in historical writings or as traditions passed down from
several generations back. For example, Jordanian red soil is still used today as a topical
antibiotic. Actinomycins have been extracted from this type of soil, which explains the rationale
behind its use. Chinese medicine has incorporated several plants and components that contain
antibiotic-like molecules, most notably qinghaosu, or Artemisia plants, which contain an
ingredient used in modern antimalarials [3].
The Modern Antibiotic Era
Paul Ehrlich who developed a method for staining tubercle bacillus and is credited with
developing the foundation of gram staining, envisioned a method for discovering antibiotics
based on selective staining of cell types. Ehrlich sought to find a “magic bullet,” or chemicals
that have high selectively in targeting pathogens but a low affinity for affecting the patient. To
do this, Ehrlich tested hundreds of organically synthesized arsenic derivative compounds in a
rabbit animal model infected with syphilis. Ehrlich discovered a compound that he called
“salvarsarin,” to treat syphilis and it was considered a great improvement over the standard of
care at the time, which was an inorganic mercury compound. This was one of the first systematic
attempts to discover an antimicrobial chemotherapy. Such a method of discovery was expensive
and timely, as it was screened in an animal model. In addition, salvasarin was not without side
effects, indicating that it was not the perfect “magic bullet” that Ehrlich envisioned [4].
Even with advancements in drug discovery, the available chemotherapies for infectious
diseases continue to have side effects in the patient. The most commonly used antibiotics cannot
be taken without risk, as can be seen in Table 1.1 below. The fact that pathogen-targeting drugs
are not perfect “magic bullets,” begets the question of “is it time to either change or expand the
targets of our antibiotic chemotherapies?” Specifically in our research, we aim to see if we can
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identify those host proteins that pathogens exploit in order to exert their toxic effects within the
host. Such as approach is relatively new in the field of infectious diseases. However it is
important to note that drugs for other diseases that are not caused by pathogenic agents due in
fact aim to correct the disease by altering factors within the host. The simplest example that
comes to mind, are over-the-counter pain medications. Ibuprofen works in the host by inhibiting
the production of prostaglandins, lipid like compounds that are a result of inflammation.
Table 1.1: Common antibiotics and their side-effects
Penicillin

Hypersensitivity

Cephalosporin

Hypersensitivity

Clindamycin

diarrhea, psuedomembrane colitis

Aminoglycoside

kidney damage, neurotoxicity

Metronidazole

GI disturbance, seizures

Vancomycin

neurotoxicity, thrombophlebitis

Chloramphenicol

bone marrow suppression

Erythromycin

mild GI disturbance

Tetracyclin

Tooth discoloration, photosensitivity

The Discovery of Penicillin
Even before that fateful day in 1928 when Alexander Fleming returned from his summer
vacation to find his staphylococci plates contaminated with mold, there are accounts of people
using mold-contamination in an attempt to treat infections. However it was Fleming’s
observation that eventually led to the mass production of Penicillin. Thanks to being able to
produce Penicillin in mass quantities, several hundreds of lives were saved from septicemia and
blood poisoning during World War 2 [5].
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Figure 1.1: An advertisement for Penicillin during World War II [5]

This discovery also ushered in the golden age for discovery and development of
antibiotics. As can be seen in Figure 1.2 below, several major antibiotic therapies were
developed in the 1940s [6]. In Chapter 2 of this report, we describe studies that strongly echo
Alexander Fleming’s discovery, in which varying concentrations of drugs from a drug library
were tested for their ability to inhibit the growth of the fungal pathogen, Candida albicans. Drug
hits were then tested for their cytotoxicity in cellular assays to assess their safety profiles as
potential repurposed drugs.
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Figure 1.2: The discovery and consequent development of antibiotic resistance [6]

Fleming’s Warning
Arguably as important as Fleming’s discovery of Penicillin, was the warning that
accompanied it. Fleming observed that his bacterial samples had the ability to evolve resistance
to Penicillin and he stated, “The thoughtless person playing with penicillin treatment is morally
responsible for the death of the man who succumbs to infection with the penicillin-resistant
organism [7].” One of the biggest threats of modern times as seen by scientists who study
infectious diseases, is the emergence of drug resistance, which is predicted to ten million people
by the year 2050. Drug resistance can be attributed to many factors such as, over-prescription of
antibiotics (physicians often prescribe them when they suspect a viral infection), over-use of
sanitizers, prevalent use of antibiotics to raise livestock, improper disposal of antibiotics, and
improper use of antibiotics (such as not finishing a course) [8]. It remains to be tested, and is an
interesting line of inquiry, whether a drug that interferes with host machinery, is less likely to
become resistant than a drug that is designed to be specifically toxic to the pathogen.
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Thesis Scope
The past century has seen the golden era of antibiotic discovery and a significant
reduction in mortality from infectious diseases. Unfortunately, developing countries are seeing
more incidences of infections (viral, bacterial, fungal, and parasitic) that are becoming resistant
to the last lines of treatment by the strongest chemotherapies [9]. In developing countries as well
as all over the world, ease of travel and increasingly populated locations allows for the
reemergence of infectious diseases as well as emergence of new epidemics. The truth remains
that drug discovery for infectious diseases needs to be a continuous effort, as well as an effort
that requires new approaches and creativity [10]. In this dissertation, I will highlight the novel
ways with which we attempt to discover drugs for pathogenic agents, with an emphasis on
anthrax toxins. Our creative approach involves the search for drugs that disrupt host machinery
that are commonly exploited by pathogens, rather than the common method of finding drugs that
attempt to disrupt the pathogens directly.
We have attempted different methodologies in order to accomplish the discovery of hostoriented drugs, or what we termed as those drugs that will target host proteins exploited by
pathogens (HPEP). In the research that resulted in the third chapter, we focused on finding a drug
that disrupted the anthrax intoxication pathway. In order to accomplish the discovery of an HPEP
through a cell survival assay, we chose to conduct an additional toxin-challenge cell assay with a
toxin that has a similar method of cell entry to that of anthrax toxin, but that is different in its
enzymatic mechanism of lethality. The hope was that a drug that could save cells from both
toxins, would likely be an HPEP. An ideal toxin that matched our criteria was diphtheria toxin,
in that its method of entry is very similar to the method of entry of anthrax toxin, having both a
receptor binding component, as well as acidification of the early endosome to release the
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enzymatic toxic component into the cytosol. Anthrax lethal toxin is a zinc metalloprotease while
diphtheria toxin is an ADP ribosyltransferase [11] [12]. After identifying drug hits from our cell
screens, we sought to show the mechanism of repurposed-drug mechanism.
Hosts and pathogens have evolved alongside each other, placing reciprocal selective
pressure on each other in order to adapt [13]. As such, bacteria and their toxins often exploit host
cellular mechanisms to gain entry into host cells [14] [15]. There is extensive literature
describing the mechanism by which anthrax toxin is able to enter cells as is summarized above.
Other toxins and pathogenic agents share some of the HPEPs that are necessary for the anthrax
toxin internalization pathway. By identifying drugs that disrupt HPEPs, we were able to identify
other pathogens that could be disrupted by the same drug, giving us a broad-spectrum therapy.
One example was showing that our anthrax toxin drug, which worked by means of lowering host
Cathepsin B, (necessary for autophagic flux) is also necessary for the Ebola virus. These studies
can also be found in Chapter 3.
In subsequent studies, we attempted different methodologies for identifying HPEPs. In
Chapter 4, we discuss multiplex screening, involving simultaneous toxin/cell assays with
protein-based screens for drugs that are capable of interfering with host caspases, a family of
host proteins that are expressed when cells are under stress, and ready to undertake programmed
cell death [16]. In Chapter 5, we screen the drug library in protein-based assays and afterwards
tested the drug hits for the ability to save cells from toxins without being cytotoxic themselves.
Although it had been done before, the entirety of our drugs screens utilized a library of
previously FDA approved drugs that are off patent. It was our hope that using this tool could
help us to identify drug hits with already known safety, pharmacokinetic and pharmacodynamic
profiles (Ashburn 2004). In a time where pharmaceutical companies don’t typically endeavor on
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creating drugs for infectious diseases, due to their low profitability and a saturated market,
repurposing an old drug creates a situation where it is more quick and affordable to find therapies
and get them approved for new indications [17].
Figure 1.3: Antibiotics approved by the FDA over time [17]

In the case of an infectious disease outbreak, such as the Ebola crisis in 2013 and the Zika
virus spread in the summer of 2016, finding a previously approved therapy can be accomplished
quickly and previously established manufacturing and distribution channels make it easier to get
the chemotherapy to the patients and control the quick spread of disease as soon as possible.
As it is known, only one infectious disease, smallpox, has been completely eradicated
[18] [19]. Other infectious diseases, especially viruses, continue to re-emerge or newly emerge,
often causing serious health crises around the globe (Brower 2003). With drug repurposing, it is
possible to quickly design and execute a drug screen to identify a potential solution for an
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infectious disease epidemic. With a repurposed drug there is the possibility of a quicker road to
FDA approval due to the known safety data from the approval of that drugs’ previous indication.
Figure 1.4: The global emergence and re-emergence of infectious diseases [20]

Anthrax
Robert Koch, the German physician and microbiologist, is credited with discovering that
anthrax is the disease caused by the gram-positive bacteria, Bacillus anthracis. Koch made the
discovery in 1896, after mass livestock deaths across Europe [21]. This discovery was
significant, as it was the first time that a link was made between an organism and a disease. The
bacteria are often found in the soil where it may remain in a hardy spore-form for several
decades, despite harsh conditions [22]. Livestock will usually pick up the spores while they
graze, and pass on the bacterium to any animals or humans that come in contact with them.
There are three main routes of infection for anthrax (in order of least lethal to most lethal),
cutaneous, gastrointestinal, and pulmonary. Recently in northern Europe, incidences of anthrax
have been spread by contaminated needles, directly into the bloodstream and muscles. The
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symptoms of bloodstream anthrax are similar to those of cutaneous anthrax. Anthrax in itself is
difficult to diagnose, as the inhalational disease is similar to symptoms of the flu or a whole slew
of other diseases [22].
Figure 1.5: Gram stain of Bacillus anthracis [23]

Anthrax infections are rare in developing countries, however most people are aware of it
due to its use as a biological weapon, during ancient times, World Wars I and II, and most
recently in 2001, when aerosolized spores were sent to various American senators and news
media offices. As a result of the postal anthrax attacks, five individuals were killed. It is
estimated that between 5,000 - 8,000 spores are sufficient to cause inhalational anthrax, with
there being a clear genetic component contributing to anthrax toxin sensitivity (Martchenko). It
is known that several governments and terrorist organizations have worked to weaponize
anthrax. Despite the potential for being nefarious, anthrax is a wonderful tool for studying
pathogenic mechanisms.
A lot is understood about the way in which anthrax spreads and becomes lethal within the
host. Three toxic proteins produced by the bacterium are credited with largely damaging host
10

cells, in order to allow infection to spread. The three toxic components are: protective antigen
(PA), lethal factor (LF), and edema factor (EF). PA is a receptor-binding domain, that allows for
the internalization of the other two enzymatic toxins, EF and LF. Our research focuses on the use
of LF and PA only. Anthrax toxins are necessary in the initial stages of infection in order to
suppress the innate host immune response to enable systemic infection. Anthrax toxins inhibit
the scavenger functions of myeloid cells, including neutrophils and macrophages, allowing the
vegetative bacteria to propagate. At later stages of infections, the high amounts of toxin kill the
host; lethal toxin (LT) destroys cardiomyocytes and smooth muscle, while (edema toxin) ET
affects hepatocytes in the liver [11].
Figure 1.6: The roles of lethal toxin and edema toxin in anthrax infection [11]

Due to anthrax toxins significant role in contributing to lethality, it is no surprise that
antibiotic treatment alone is not very effective unless given in the early stages of disease. It is for
this reason that there is value in discovering anthrax antitoxins. In addition, anthrax toxins
provide an interesting disease model, as they utilize and exploit host mechanisms to exert their
lethal effects. Much is known about the mechanisms exploited by anthrax toxins, and it’s been
11

observed that those host proteins are also exploited by different pathogens. Identifying
chemotherapies that can interfere with lethal toxin internalization, has allowed us to explore
broad-spectrum therapies, which is a major theme of this report. Finally, we took advantage of
the observation that some pathogenic agents, specifically proteins, also belong to the same
protein families as the host proteins they exploit. Using this knowledge, we attempted to
indentify drugs that could simultaneously interfere with a pathogenic agent and boost host
defenses (discussed in Chapter 5).
Our research may provide a creative and quicker approach to drug discovery, that may
have broad-spectrum applications, and potentially reduce antibiotic resistance. This approach can
be applied to other types of host proteins and for other pathogens and pathogenic agents.
However, our approach is not without limitations. For example, a therapy designed to target a
class of proteins, may not be specific enough, binding to other irrelevant yet similar proteins,
causing side effects. It may be possible to improve upon our drugs in many ways. For example,
indentifying the active chemical motif of our drugs and then engineering them to be more
effective. Another method to improve our therapies involves combining drugs, with the hope of
reducing the amounts of both drugs, while increasing the efficacy of the therapy as a whole. Our
methodologies allowed us to identify drugs that inhibit proteins in the anthrax internalization
pathway, and we were able to use our drug hits to suppress other pathogenic agents that exploit
similar proteins. As a result of our research, we have compiled a database of all of the drugs in
the John Hopkins Clinical Compound Library, and how they performed in a series of cellular and
FRET assays involving anthrax intoxication host proteins. Such information is invaluable and
can be the basis for future therapies for infectious diseases.
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Chapter 2

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Kevin Kim, Leeor Zilbermintz, and Mikhail Martchenko

Abstract
The high cost and prolonged timeline of new drug discovery and development are major
roadblocks to creating therapies for infectious diseases. Candida albicans is an opportunistic
fungal pathogen that is the most common cause of fatal fungal infections in humans and costs
$2–4 billion dollars to treat in the US alone. To accelerate drug discovery, we screened a library
of 1581 existing FDA approved drugs, as well as drugs approved abroad, for inhibitors of C.
albicans. The screen was done on YPD yeast growth media as well as on the serum plate assay
developed in this study. We discovered that fifteen drugs, all which were originally approved for
treating various infectious and non- infectious diseases, were able to kill Candida albicans.
Additionally, one of those drugs, Octodrine, displays wide- spectrum anti-microbial activity.
Compared to other selected anti-Candida drugs. Octodrine was shown to be one of the most
effective drugs in killing serum-grown Candida albicans without significantly affecting the
survival of host macrophages and skin cells. This approach is useful for the discovery of
economically viable new therapies against infectious diseases.

Keywords: Antifungal, Drug-discovery, Off-label drug use, Small molecules
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Background
While almost all of us possess Candida albicans in our oral cavity, gastrointestinal tracts,
genitourinary tracts, and on skin as a relatively harmless commensal organism, C. albicans is a
major systemic fungal pathogen in humans [1]. Candida evades and escapes from the host’s
innate immunity, causing irritating and recurrent infections that can range from thrush in
immunocompetent

colonized

hosts,

to

life-

threatening

systemic

infections

in

immunocompromised in- dividuals such as patients with HIV, or those receiving
immunesuppressing cancer chemotherapy and corticosteroids. Surprisingly, only 10 to 20% of
individuals who develop bloodstream Candida infections are seriously immunocompromised. A
large majority of patients develop Candida infections because they have become more
susceptible while hospitalized due to the use of broad-spectrum antibiotics, surgery, and
intravenous catheters. As a result, infections from C. albicans ranks as the fourth most common
hospital-acquired infection in the United States. The cost of treating bloodstream Candida
infections is $2– 4 billion per year in the US alone [2]. In the US, annual incidence of systemic
candidiasis is approximately 70,000 cases per year, which results in the death rate of about 30 to
40%, even after treatment with antifungal therapy [3].
The situation is especially grave in cancer patients. The incidence of Candida infection in
all cancer patients is very high, ranging from 40 to 88 % [4] [5]. The mortality rate among the
Candida infected cancer patients reaches an alarmingly high 75% amongst the Filipino and
Pacific Islanders [5]. Early antifungal treatment, although poorly tolerated by the host, is
mandatory to improve the survival of cancer patients. Unfortunately, 30% of Candida isolates
are resistant to all antifungal treatments [6].
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Host serum plays a prominent role in the pathogenicity of C. albicans. On the one hand, serum
promotes morphological switching of Candida from yeast to hyphal forms, which is necessary
for its evasion of phagocytosis and organ colonization [7]. On the other hand, serum is known to
inhibit the activity of known antifungal drugs [8]. Taken together, these laboratory observations
explain in part the clinical mortality observed during Candida blood infections, even when
patients are treated with antifungals [5].
Several clinical and laboratory data suggests that currently available antifungal therapies
are mostly ineffective in treating Candida infections [9]. Despite extensive research dedicated to
the development of new therapeutic strategies, there are only a limited number of available drugs
to fight against invasive fungal infections. Indeed, only four molecular classes targeting three
distinct fungal metabolic pathways are currently used in clinical practice to treat systemic fungal
infections. These include: fluoropyrimidine analogs, polyenes, azoles, and echinocandins [9]
[10]. However, the efficacy of some of these drugs is severely limited because of their
unacceptable toxicity, poor activity in blood, or the emergence of resistance; thereby
underscoring an urgent necessity for new antifungal agents. Several other classes, such as
morpholines and allylamines are only used as topical agents due to either their poor efficacy, or
severe adverse effects when administered systemically [9] [10].
Unfortunately, the development of an entirely new drug is a long and expensive process.
New drugs have to undergo an arduous approval process by the FDA in order to establish safety
of the drug for human consumption [11]. We propose that the repurposing of existing FDAapproved drugs as antifungal agents may decrease the time and effort of bringing drugs with
novel antifungal activity from the bench to the bedside. Recently, another group investigated the
ability of FDA-approved drugs to inhibit C. albicans biofilm formation by screening the

17

Prestwick Library, a commercially available chemical library of 1200 drugs [12]. However, C.
albicans biofilm formation is just one of many pathogenesis strategies, such as yeast-to-hyphal
phenotypic switching, white-opaque phenotypic switching, ability to adhere to mammalian
tissues, and secretion of aspartyl proteinases [1] [7]. The goal of this study is to identify drugs
capable of killing blood-borne Candida albicans, and we use serum as an in vitro surrogate of
host blood. To this end, we have tested the anti-Candida activity of drugs from the Johns
Hopkins Clinical Compound Library (JHCCL) [13] on Candida grown on serum-containing
media. This library consists of drug-compounds that are FDA-approved with a diverse range of
functions, mechanisms of action and well- characterized pharmacological and toxicological
properties.

Methods
Candida albicans and bacterial strains
Strain SN250 is the wild type reference strain of C. albicans. It serves as the reference
strain for our genetic knockout library screen. It is derived from the wild type strain SC5314, a
human clinical isolate recovered from a patient with generalized candidiasis [14]. SN250 was
used for drug screening experiments. The bacterial strains consisted of Bacillus cereus strain
10987 and Escherichia coli strain C600. The genetic screen for mutant sensitivity to Octodrine
was tested with three C. albicans libraries that were previously created in [15] [16] [17].

Media and growth conditions
C. albicans strains were cultured in liquid YPD medium at 30 °C overnight. E. coli and
B. cereus were cultured in liquid LB medium at 37 °C and 30 °C, respectively, shaking
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overnight. A novel method to incorporate fetal bovine serum to agar was devised. Fetal bovine
serum was preheated in a water bath set at 65 °C. We found that isothermal conditions of the two
mixtures eliminated the formation of foam upon coalescence. The agar solution for the serum
mixture consisted of 16 g agar, which was then brought up to 300 ml with nanopure water. The
agar solution was then autoclaved at 120 °C for 45 min. The agar and serum mixtures were then
amalgamated while in their isothermal states.

Chemicals
An FDA-approved drug library comprising of 1500 drugs was purchased from Johns
Hopkins, titled, Johns Hopkins Clinical Compound Library (JHCCL) version 1.0. The drugs
arrived as 10 mM stock solutions in sealed microtiter plates and were made using DMSO or
water as solvents. Drugs were arrayed in 96-well plates and screened at a stock concentration of
10 mM. Drugs were from Fisher and Sigma and were of the highest purity available. The library
was stored at −20 °C until use. Prior to use, the library of drugs was thawed at room temperature.
Drugs of interest were isolated and reproduced from prepared 10 mM solutions. Antimycin A,
Captan,

Chlorquinaldol,

Methylbenzethonium

Clotrimazole,

Chloride,

Disulfiram,

Miconazole,

Fluvastatin,

Nitroxoline,

Mycophenolic

Octodrine,

Pyrithione

Acid,
Zinc,

Fluconazole, and Octanoic Acid were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Nifuroxime was purchased from MP Biochemicals (Solon, OH, USA). All drugs were prepared
to 10 mM using DMSO as the solvent. DMSO was purchased from Amresco® (Solon, OH,
USA). Fetal bovine serum (Triple Membrane 0.1 µm filtered) was purchased from GeneMate
BioExpress (Kaysville, UT, USA).

19

Screening assay
The sensitivity of C. albicans to drugs was assessed by a chemical screen. The
absorbance at optical density at 600 nm (OD600) of yeast and bacterial overnight cultures were
determined for each of our experiments. The absorbance values were then converted to cells/ml
using McFarland’s scale. Twenty five million Candida cells were added to all 10 cm petri dishes;
600 million bacterial cells were added to all 10 cm bacterial petri dishes. Five microlitre of each
drug was placed directly on the agar surface using a multichannel pipette and slight contact of
the tip to the agar made to leave an impression to facilitate later analysis. Drugs that were
replicated were done on petri dishes, following the same protocol in at least five independent
experiments. For the replica- tion studies, only a single drug was placed per plate. The plates
were incubated at either 25 or 37 °C for 24 h. The drugs-of-interest were selected on their ability
to produce a distinct zone of inhibition of fungal growth greater than the zone made by DMSO
alone and at the same time that is comparable to, if not greater than the positive control,
Fluconazole. The zones of inhibition were quantified by measuring their diameters in mm, as
recommended by the Clinical Laboratory Standards Institute (CLSI) procedures outlined in the
manual M44- A2 [18] [19]. In addition, we utilized the software ImageJ [20] to digitally quantify
the magnitude of every zone of inhibition.
E. coli and B. cereus were cultured overnight in liquid LB media at 37 and 30 °C
respectively. The sensitivity of E. coli and B. cereus to Octodrine was assessed by spreading 6 ×
108 cells of their respective overnight cultures onto petri dishes containing solid LB media. 5 µl
of neat Octodrine was placed directly on the agar surfaces. The plates with E. coli were
incubated at 37 °C, while plates with B. cereus were incubated at 30 °C for 24 h.

20

Determination of minimal effective drug concentrations by drug diffusion susceptibility testing
Plates inoculated with C. albicans were prepared using the protocol described above. To
elucidate the ability of the varying concentrations of drugs to form zones of inhibition, two-fold
serial drug dilution experiments were performed. To perform the first two-fold dilution, one part
of the 10 mM stock solution was mixed with one part DMSO. Each subsequent dilution was
done with aliquots from the prior dilution mixed with equal parts of DMSO. 5 µl of each drug
dilution was spotted onto a lawn grown on YPD plate, as well as 5 µl of DMSO as a negative
control. Dilutions beyond 0.07813 mM that were still forming a significant zone of inhibition
were further diluted on a separate plate. Drug-treated plates were then incubated at either 25 or
37 °C for 24 h. Two- fold serial dilutions of Octodrine were done on YPD and Serum plates with
undiluted Octodrine as the most con- centrated solution.

Genotypic mutant screening against Octodrine
Each C. albicans knockout strain from one of the three C. albicans libraries [15] [16]
[17] was cultured in individual wells of 96 well plate in 100 µl of YPD media overnight at 30 °C.
5 µl of each Candida knockout overnight culture was spotted onto a YPD solid plate using a
multichannel pipette. The cells were then left to absorb into the YPD plates for 1 h at 25 °C.
Using a multichannel pipette, 5 µl of Octodrine 10 mM was spotted directly on top of the C.
albicans cells. The plates were then placed in an incubator set at 30 °C and left overnight.
Analysis of plates consisted of isolating any strains that exhibited resistance to 5 µl of 10 mM
Octodrine. Resistance was noted by the ability of the Candida cells and the subsequent drugtreated spot to lack a zone of inhibition.
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Mammalian cell culture, drug treatment, and survival assay
RAW264.7 mouse macrophage cells (ATCC number TIB- 71) and human melanoma C32
cells (ATCC number CRL-1585) were maintained in DMEM (Sigma-Aldrich) supplemented
with 10 % FBS (Bioexpress) and 100 µg/mL penicillin and 100 µg/mL streptomycin.
Mammalian cells (10,000 per well) were seeded in 96-well plates (100 µl/ well) 24 h before the
assay. During the assay, 1 µl of 10 mM drug was added to 100 µl of cell-containing media. Twofold serial dilutions of the media were performed. RAW264.7 and C32 cells were treated with
drugs for 24 and 48 h respectively, and determination of cell viability by 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed as described in ??? [21].
Each data point shown in the figure for MTT assays represents the average of results from at
least two wells in each of at least two separate experiments. Cell viability is shown as the
percentage of survivors obtained relative to untreated cells grown in media only (100 %).

Image capture and image processing
All images were taken with an 8MP iSight camera with an aperture size of F2.4 and
touch-to-focus capabilities. Images were standardized with a universal template to allow for
direct comparison between images. Images are stock and unaltered by any graphics editing
software.

Results
Moderate ability of Fluconazole to kill serum-grown Candida albicans at 37 °C
It has been reported that host serum markedly inhibits growth of the human fungal pathogen,
Candida albicans [22] [23] [24]. We have confirmed these observations by showing that
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Candida wild type strain SN250 [15] is unable to grow in liquid 100 % Fetal Bovine Serum at
either 25 or 37 °C (data not shown). However, during the course of our experiments, we have
observed that Candida is able to grow and establish a lawn on solid serum plates containing 62.5
% v/v FBS and 37.5 % v/v agar solution, at both temperatures (Fig. 1a).
Figure 2.1: Analysis of C. albicans strain SN250 treated with various drugs and diagram

The search for new antifungal drugs. a Analysis of C. albicans strain SN250 treated with various drugs. The strains were grown
and exposed to drugs determined to be drugs of interest by our chemical screen. The size of the zone of inhibition on each image
is shown with the same scale (mm), with standard deviation values are shown in Additional file 1: Table S1. Plates were treated
with drugs after spreading of 200 µl of liquid Candida culture and left to incubate overnight in either 25 or 37 °C. b The hits were
classified into three classes: Antifungal, Antimicrobial, and Miscellaneous drugs. Numbers within grey circles represent number
of drugs of each class in JHCCL, while numbers in the transparent middle circle shows the number of hits of drugs from our
screen.
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We investigated whether Fluconazole, the widely used anti-Candida drug, was able to kill
C. albicans on solid serum plates. While Fluconazole was shown to be an effective inhibitor of
Candida growth on standard solid YPD plates, (Fig. 1a), we observed that Fluconazole
moderately inhibits the growth of Candida on serum plates (Fig. 1a and Additional file 1: Table
S1). It should be noted, however that Fluconazole formed prominent zones of inhibition on the
solid YPD plates. In addition, we observed that Fluconazole exhibited diminished effectiveness
at forming zone of inhibition at 37 °C compared to 25 °C (Fig. 1a and Additional file 1: Table
S1). We decided to assess the drug-pathogen interactions at 25 °C in additional to body
temperature because there is a serious problem of Candida growth in catheters where it may be
exposed to serum at room temperatures [25].

Screening of inhibitors of Candida albicans lawn formation
In light of the moderate effectiveness of Fluconzole to kill C. albicans in serum at the
physiologically relevant temperature (37 °C), and in search for alternative anti-fungal drugs, we
decided to screen the library of chemicals [13] approved by the FDA for human use for their
ability to kill Candida albicans. JHCCL consists of 1581 FDA-approved drugs, as well as drugs
approved abroad, consisting of small molecules (10 mM) that are used as treatments for a variety
of diseases, including, but not limited to: infectious, neurodegenerative, psychiatric,
cardiovascular diseases and cancer.
We identified inhibitors of Candida growth formation by performing a primary screen on
the 1581 drugs belonging to the JHCCL. We plated Candida on solid YPD and serum plates, and
placed 5 µl of each 10 mM drug on top of the fungal lawn. We tested the effect of exposure to
each of the drugs from the library on their ability to inhibit Candida growth, as well as their
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ability to form a zone of inhibition within the fungal lawn. Based on this screen, we identified 15
drugs that inhibit Candida growth on solely YPD or on both YPD and serum plates in at least
five independent experiments at two temperatures, 25 °C and 37 °C (Fig. 1a). We classified the
15 hits into three different classes to facilitate interpretation of our results. They were: 6 hits
from 32 known antifungals, 5 hits from 359 antimicrobials/antiseptics, and 4 hits from 1190
other multifunctional drugs (Fig. 1b). While these drugs were chosen in these screens for their
ability to inhibit C. albicans lawn formation, the actual levels of inhibition varied from weak to
strong inhibition (Fig. 1a and Additional file 1: Table S1).
All 6 selected antifungal drugs, Antimycin A, Captan, Clotrimazole, Fluconazole,
Miconazole, and Pyrithione Zinc showed strong inhibition of Candida growth on YPD plates at
25 °C and 37 °C (Fig. 1a and Additional file 1: Table S1). However, with the exception of the
pesticide Captan, all of the antifungals exhibited weak inhibition of Candida growth on serum
plates (Fig. 1a and Additional file 1: Table S1).
Out of the five antimicrobial/antiseptic drugs selected by our screen, Chlorquinaldol and
Methyl-benzethonium chloride displayed the strongest inhibition of C. albicans growth on serum
plates. Nifuroxime, Nitroxoline, and Octanoic acid showed weaker inhibition of Candida growth
on serum plates (Fig. 1a and Additional file 1: Table S1).
Interestingly, from a drug-repurposing point of view, 4 drugs from 1190 of the other
multifunctional drugs, showed anti-Candida activity on YPD plates (Fig. 1a and Additional file
1: Table S1). Of those, Fluvastatin and Mycophenolic acid showed very strong inhibition of YPD
grown Candida, but failed to inhibit its growth on serum plates (Fig. 1a and Additional file 1:
Table S1). The other 2 drugs, Disulfiram and Octodrine showed a consistent moderate-to-weak
anti-Candida activity on YPD and serum plates (Fig. 1a and Additional file 1: Table S1).
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Diffusion susceptibility testing of the hits obtained from the screen
The 15 hits from the primary screen consisting of antifungals, antimicrobials, and
miscellaneous drugs were tested in diffusion susceptibility assays in order to determine their
potency against C. albicans lawns. These confirmatory screenings were performed over a range
of drug concentrations, where 5 µl of drugs within the range of 10 mM to 0.3 µM were applied
on YPD-grown Candida cells and plates were incubated for 24 h. YPD plates were chosen as the
testing media since some of the drug hits were ineffective in inhibiting fungal growth on serum
plates. The efficacy of each drug was evaluated by estimating the inhibitory concentration at
which the drug formed a zone of inhibition on a fungal lawn of YPD plates.
We found that with the exception of Fluconazole and Captan, all antifungals were able to
inhibit Candida growth in the µM drug range (Fig. 2 and Additional file 1: Table S2). All five
antimicrobial and antiseptic drugs were only able to inhibit fungal growth in the mM drug
concentrations (Fig. 2 and Additional file 1: Table S2). Surprisingly, among the drugs approved
for non-infectious disease treatments, Fluvastatin was able to inhibit C. albicans growth in the
µM drug concentration, while the rest of the drugs were only inhibitory in the mM drug
concentrations.
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Figure 2.2: Agar drug diffusion susceptibility assay of Candida albicans SN250

Plates were treated with various concentrations of drugs after spreading of 200 µl of liquid Candida culture and left to incubate
overnight in either 25 or 37 °C. The middle of the plate served as the negative control, DMSO. Dilutions that failed to exhibit
discernable inhibition after one plates were further diluted a second time. The size of the zone of inhibition on each image is
shown with the same scale (mm), with standard deviation values are shown in Additional file 1 Table S2

Broad-spectrum antimicrobial properties of Octodrine
Although nine antimicrobial and non-antimicrobial drugs we discovered have not been
approved by FDA to treat fungal infections, eight of them were found previously to kill Candida
albicans [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39]. Octodrine, the drug
previously used as a decongestant [40] [41] showed an ability to kill serum-grown C. albicans
when applied at 10 mM 5 µl drop (Fig. 1). Furthermore, Octodrine is the only drug that has not
been tested to kill fungi previously. We wanted to investigate whether the application of an even
higher concentration of Octodrine would augment its antifungal properties. To test this, we
applied 5 µl of neat, undiluted Octodrine, which is produced in a liquid form, as well as its twofold serial dilutions on the serum and YPD grown Candida lawn. We discovered that the
undiluted amount of Octodrine was effective in eliminating the fungal growth (Figs. 3 and 4 and
Additional file 1: Tables S3 and S4). We also observed that Octodrine is more effective in
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inhibiting serum grown Candida compared to YPD grown Candida, as the inhibitory
concentrations of Octodrine were more pronounced on serum than on YPD plates (Fig. 3,
Additional file 1: Table S3).

Figure 2.3: Agar Octodrine diffusion susceptibility assay of Candida albicans SN250.

Plates were treated with various concentrations of Octodrine after spreading of liquid Candida culture and left to incubate
overnight in either 25 or 37 °C. The equal volume of negative control, DMSO, was also included. The size of the zone of
inhibition on each image is shown with the same scale (mm), with standard deviation values are shown in Additional file 1 Table
S3

Figure 2.4: The sensitivities of Candida albicans, Escherichia coli, and Bacillus cereus to neat
Octodrine
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Plates were treated with 5 µl of undiluted Octodrine after spreading of 200 µl of liquid Candida (25 × 106 cells) or bacterial
cultures (600 × 106 cells) on 10 cm petri dish and left to incubate overnight in either 37 °C for C. albicans and E. coli or in 30 °C
for B. cereus. The size of the zone of inhibition on each image is shown with the same scale (mm), with standard deviation values
are shown in Additional file 1 Table S4

In order to identify Candida proteins and signaling pathways that mediate the lethality of
Octodrine, we screened three C. albicans knockout libraries, collectively consisting of 908
mutant strains lacking one of the previously demonstrated virulence genes, for any alterations in
sensitivity to 10 mM Octodrine. These libraries consisted of 647 mutant strains lacking one of
the essential virulence genes [15], 96 cell wall protein mutants [42], and 165 transcription factors
mutants [43]. We found that all Candida mutants were as sensitive to 5 µl of 10 mM Octodrine
as the wild type strain (Additional file 1 Figure S1).
We hypothesized that Octodrine may kill microorganisms by targeting their non-protein
cellular components. To investigate this we tested the sensitivities of Escherichia coli strain
C600 and Bacillus cereus strain 10987, gram-negative and gram-positive bacteria, respectively,
and frequent disease-causing bacteria, to Octodrine. These bacterial strains were chosen because
they are wild type strains with known genotypes and genomes [44] [45]. We observed that 5 µl
of neat Octodrine formed a prominent zone of inhibition in both E. coli and B. cereus lawns
(Fig. 4 and Additional file 1: Table S4), which suggests that Octodrine possesses wide spectrum
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antimicrobial properties.
Since Octodrine was one of the most prominent drugs that killed C. albicans in serum,
we tested the sensitivity of mouse macrophage cell line RAW264.7 to Octodrine, and compared
it to the rest of selected drugs. Since Octodrine stock was dissolved in DMSO, we had to test the
sensitivity of the cell line to this solvent alone. Cell viability was determined by MTT assay
(Methods) and was calculated as the percentage of surviving cells in various chemical
concentrations relative to cells treated with media alone. We observed that the sensitivity of
mouse macrophages to Octodrine was the close to the sensitivity to the DMSO alone (Table 1).
This strongly suggests that Octodrine concentrations that kill Candida albicans in serum
(Fig. 1a) do not affect the survival of host phagocytes. The sensitivity of RAW264.7 cells to
DMSO has previously been reported [46], and is consistent with the cellular sensitivity seen
here. We tested the sensitivity of RAW264.7 macrophage like cells because macrophages are
first line of defense against Candida, and knowing the sensitivity of those cells to antifungal is
an important question. We confirmed these observations by testing sensitivity of human skin
melanoma cell line, C32 (Table 1). With the exception of Octodrine, Floconazole, Nifuroxime,
and Fluvastatin, all other selected drugs adversely affected the survival of host cells, which
suggests that they may have undesirable side effects when used in blood. We chose this cell line
because of the relevance of skin to Candida infections.

30

Table 2.1: Minimal cytotoxic concentration (MCC) calculations for the cell lines RAW264.7 and
C32 treated with selected drugs
Drug

MCC (µM) RAW264.7

MCC (µM) C32

Fluconazole

100.00

100.00

Antimycin

3.13

0.098

Captan
Chlorquinaldol

12.50
0.20

12.50
6.25

Clotrimazole
Disulfiram

6.25
12.50

12.50
12.50

Fluvastatin

50.00

6.25

Methylbenzethonium Chloride

6.25

1.56

Miconazole

6.25

1.56

Mycophenolic Acid

0.78

1.56

Nifuroxime

25.00

25.00

Nitroxoline

6.25

6.25

Octanoic Acid

0.78

6.25

Octodrine
Pyrithione Zinc
DMSO

25.00
0.78
50.00

25.00
1.56
50.00

The solvent DMSO is used as a negative control. Mammalian cells were treated with drugs at concentrations shown. The drugs
were serially-diluted, and the MCC is defined as the first concentration of the drug, which is able to lower cell viability below
100 %. Cell viability was determined by MTT assay (Methods) and is shown as the percentage of survivors relative to cells
treated with media alone

Discussion
This study was designed to test FDA and foreign-approved small molecules drugs for
their antifungal properties, with the objective of reducing the cost and time necessary to develop
much needed anti-Candida albicans therapies. This library consists of an FDA-approved, offpatent collection of 1581 small molecules (10 mM) that are used as drugs for a variety of
diseases, including infectious, neurodegenerative, psychiatric, cardiovascular diseases and
cancer. Such an approach would rapidly expedite the drug discovery and development process
since the general pharmacology, toxicology, and pharmacokinetic properties of all these drugs
are already well established. This would facilitate the further analysis of the novel functionalities
of the established molecules because the structure, chemical properties, and biological functions
of almost all members of this library are known.
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We have developed a serum-based assay to address the limitations of currently used YPD
media, whose components do not represent in vivo components that support the growth of
Candida. The moderate-to-mild effectiveness of Fluconazole and other FDA approved antifungal
drugs on our serum assay is comparable to the effectiveness of Octodrine in killing serum-grown
C. albicans.
In our study, fifteen out of 1581 drugs displayed anti-Candida properties. Overall, all
drugs discovered in our study could be separated into three structural categories: five-membered
heterocyclic drugs, such as azoles and oxoles, six-membered heterocyclic compounds
(pyridines), and other structures (Fig. 5). The fact that we selected six drugs that were previously
approved by FDA to treat fungal infections biologically validates our approach. The six
antifungal drugs obtained as hits from the screen comprised three different chemical classes:
azoles (Fluconazole, Captan, Clotrimazole, and Miconazole), pyridine (Pyrithione Zinc), and
other structures (Antimycin A). Additionally, we found five antimicrobial/antiseptic drugs to be
effective at inhibiting C. albicans lawn formation in the screen. These drugs include general
antiseptics and antibacterial antibiotics, and comprise three different chemical classes: oxoles
(Nifuroxime), pyridines (Nitroxoline and Chlorquinaldole), and other structures (Octanoic acid
and Benzethonium Chloride) (Fig. 5). The fact that these five other drugs that were approved by
FDA to treat other non-fungal infectious diseases were also observed to kill Candida albicans
shows that these drugs could be repurposed to be broad-spectrum anti-microbial drugs.
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Figure 2.5: Chemical structures of 15 drugs shown to have anti-Candida albicans activity in our screen

All drugs were categorized into 3 classes: 5-membered heterocyclic (Azoles and Oxoles) and 6-membered heterocyclic
(Pyridines) compounds, as well as drugs of other structures. The FDA approved applications are shown in green. Substructures
are indicated in red.
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Lastly, from the point of view of drug repurposing, the most interesting class of drugs
would be the one with demonstrated activity against a variety of diseases, but with no known or
characterized antifungal activity to date. From the screen, we found four drugs belonging to this
class to be effective in preventing Candida growth. These drugs have been designed for several
indications, including immune-suppression (Mycophenolic acid), deterrent of alcohol
consumption (Disulfiram), antihyperlipidemic (Fluvastatin), and decongestant (Octodrine).
These drugs comprise three different chemical classes: azole (Fluvastatin), oxole (Mycophenolic
acid), and other structures (Disulfiram and Octodrine) (Fig. 5). These four drugs that were
approved to treat non-infectious diseases showed antifungal properties and thus, could be
repurposed as new antifungal drugs.
Recently, another group investigated the ability of FDA-approved drugs to inhibit C.
albicans biofilm formation [12] by screening the Prestwick Library, a commercially available
chemical library of 1200 drugs. Interestingly, the authors of that paper discovered several
antifungal drugs in common to our study: Miconazole, Clotrimazole, and Methylbenzonium
chloride. The difference between the two studies is that Siles et al. [12] screened for drugs
capable of inhibiting Candida biofilm formation, while we looked for FDA approved drugs
capable of inhibiting the growth of non-biofilm C. albicans growth. In addition, with the
exception of Octodrine, every one out of fifteen discovered drugs in our study had been
previously tested for the ability to kill Candida albicans [26] [27] [28] [29] [30] [31] [32] [33]
[34] [35] [36] [37] [38] [39].
In this study, Octodrine, which was previously used as a decongestant and registered
under the name of Vaporpac (Medley & James Laboratories) [40] [41], was a drug that had not
been previously established as an anti-fungal. We observed that although its anti-Candida
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activity was mild on YPD, it displayed one of the best Candida growth inhibition on serum
compared to other drugs. It also has a potential to be one of the safest of the discovered drugs
because it did not affect the sensitivity of mammalian cells significantly. The fact that no C.
albicans mutants showed a decrease in sensitivity to Octodrine argues against the potential
emergence of Octodrine-resistant Candida strains, and favors the usage of this drug as a new
antifungal treatment against Candida. In addition, we showed that Octodrine is capable of killing
Gram-positive as well as Gram-negative bacteria, making it a desirable broad-spectrum
antimicrobial countermeasure, that probably kills microbes by targeting their non-protein
components. Octodrine was previously shown to agonize Estrogen Receptor Alpha with the
potency of 21 µM [47]. Thus, any in vivo antimicrobial activity of Octodrine in humans would
have to be in the nM range to avoid this side effect. As the pharmacokinetics of Octodrine had
been previously established in numerous animal models [48], this approach is useful for the
discovery of economically viable new therapies against infectious diseases.
Conclusions
In summary, we have screened the Johns Hopkins Clinical Compound Library, a
commercially available chemical library of FDA approved 1581 drugs, for the identification of
bioactive drugs against C. albicans growth. Our results provide the comprehensive survey of the
inhibition of Candida growth by existing drugs, one of which hadn’t been previously reported to
have antifungal properties. From a drug repurposing point of view, the identification of drugs
with no known antifungal activity and which demonstrated excellent activity against C. albicans
growth in serum opens up a valuable new avenue for the rapid development of antifungal agents,
which are urgently needed.
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Transition
Chapter 2 is the only one in this report to describe experiments that aim
to identify drugs that directly inhibit a microbe directly, specifically Candida
albicans. This chapter strongly echoed the accidental findings of Alexander
Fleming, yet in a more systematic fashion. Some important considerations for this
work involved testing library drugs at varying concentrations as well as using
serum plates to more accurately model the host environment. In addition, drug hits
were tested further for their viability in cellular assays. The following chapter
highlights our first attempts to find a host-oriented therapy. In Chapter 3, we
describe the utilization of two similar yet disparate toxins to be used in a drug
screen, with the hopes that an overlapping drug hit could potentially be hostoriented. While there was no guarantee our drug hits would in fact be hostoriented, follow-up experiments indicate that we were successful at identifying an
anthrax antitoxin.
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Chapter 3

Identification of agents effective against multiple toxins and viruses by host-oriented cell
targeting
Leeor Zilbermintz, William Leonardi, Sun-Young Jeong, Megan Sjodt, Ryan McComb, Chi-Lee
C. Ho, Cary Retterer, Dima Gharaibeh, Rouzbeh Zamani, Veronica Soloveva, Sina Bavari,
Anastasia Levitin, Joel West, Kenneth A. Bradley, Robert T. Clubb, Stanley N. Cohen, Vivek
Gupta & Mikhail Martchenko
Abstract
A longstanding and still-increasing threat to the effective treatment of infectious diseases is
resistance to antimicrobial countermeasures. Potentially, the targeting of host proteins and
pathways essential for the detrimental effects of pathogens offers an approach that may discover
broad-spectrum anti-pathogen countermeasures and circumvent the effects of pathogen
mutations leading to resistance. Here we report implementation of a strategy for discovering
broad-spectrum host-oriented therapies against multiple pathogenic agents by multiplex
screening of drugs for protection against the detrimental effects of multiple pathogens,
identification of host cell pathways inhibited by the drug, and screening for effects of the agent
on other pathogens exploiting the same pathway. We show that a clinically used antimalarial
drug, Amodiaquine, discovered by this strategy, protects host cells against infection by multiple
toxins and viruses by inhibiting host cathepsin B. Our results reveal the practicality of
discovering broadly acting anti-pathogen countermeasures that target host proteins exploited by
pathogens.

54

Introduction
Whereas medical treatments generally target specific cellular functions of patients to cure
or mitigate the effects of diseases, the strategy underlying treatment of infectious disease
treatment is to target the infecting pathogen [1]. Inevitably, and not surprisingly, the targeting of
pathogens has led to the emergence and spread among pathogens of mutational resistance to
countermeasures. Such resistance, together with a desire to expand the utility of countermeasures
by increasing their range of therapeutic efficacy, has in recent years sparked interest in agents
aimed at host functions that pathogens exploit to enter or be released from host cells [1]. Not
infrequently, multiple pathogens or toxins that affect hosts by different mechanisms use the same
host pathways [2], raising the prospect that multiplex strategies that concurrently or sequentially
screen for host functions exploited by multiple pathogenic agents may lead to the discovery of
broadly active and host-oriented infectious disease countermeasures.
Here we report the discovery, using a cell-based multiplex approach to screen a library of
FDA-approved drugs for the ability to interfere with disparately acting pathogens. We report
here, that a compound used clinically as an antimalarial agent, inhibits both the detrimental
effects of multiple bacterial toxins and the entry of Ebola and other viruses into host cells. We
further show that the broad antipathogenic actions of Amodiaquine result from its ability to
interfere with the functioning of the host protein, cathepsin B.
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Results
Screening of FDA approved drugs for inhibitors of toxin - induced cell death
In a systematic effort to identify candidates for repurposing drugs as broad-spectrum,
host-oriented, anti-toxin countermeasures, we screened members of the Johns Hopkins Clinical
Compound Library (JHCCL) [3] of 1,581 agents previously approved as drugs by the US Food
and Drug Administration for the ability to reduce lethality of RAW264.7 and C32 cells treated
either with Bacillus anthracis lethal toxin or diphtheria toxin (Fig. 1a). These toxins were chosen
because the mechanisms underlying their pathogenicity are well understood and are disparate to
each other.
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Figure 3.1: The use of Johns Hopkins Clinical Compound Library (JHCCL) to screen for inhibitors
of bacterial toxins

(a) Schematic diagram of cellular screens to identify drugs that reduce cellular lethality induced by anthrax lethal toxin, LF and
PA (LT) and diphtheria toxin (DT). (b) The distribution of inhibitors obtained in those screens, with a table showing the routes
taken by toxins to enter into cellular cytoplasm (Endocytosis), as well as the enzymatic activities of toxins (Protease or ADPrybosyltransferase (ADP-RT)). (c) Schematic depiction of the host pathway that mediates the delivery of anthrax toxin into
cytoplasm. Lethal factor (LF) and edema factor (EF) interact with a third B. anthracis-generated protein, protective antigen (PA).
Three host cell proteins CMG2, TEM8, and ITGB1 can serve as receptors for the bipartite PA/LF and PA/EF toxins. Fifteen
additional host proteins are known to assist PA binding and/or internalization.
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Between 50 and 70 percent of cells used for these assays normally undergo cell death, as
determined by MTT assay, within 6 and 24 hours of exposure to anthrax lethal toxin and
diphtheria toxin respectively, under the experimental conditions employed. A “hit” in our screen
was defined as an event where cells exposed to a compound at a concentration of 16 µM
increased cell survival by at least 16 standard deviations (~1% hit rate) above the survival of
control cells treated with either toxin, but is not cytotoxic to cells in the absence of toxins. Events
defined as “multiplex hits” interfered with cell killing by both of the toxins (Fig. 1b). Five
multiplex hits were identified and were tested further.
Anthrax toxin and diphtheria toxin enter the cytoplasm from acidified endosomes [4].
Whereas diphtheria toxin is an ADP ribosyl transferase, anthrax toxin is a protease that cleaves
host MAPKK (Fig. 1c). To identify agents that inactivate host proteins exploited by toxins, we
focused on hits that inhibit the mechanistically differently acting anthrax and diphtheria toxins.
In order to elucidate host-targets inhibited by these drugs, we used only anthrax toxin, as the host
cellular pathway that delivers the anthrax toxin into the cytoplasm is one of the best understood
pathways5 (and Fig. 1c). Anthrax lethal toxin is an exotoxin protein complex consisting of
protective antigen (PA) and lethal factor (LF), which act collectively to damage the host cell [6].
PA is an 83 kDa cellular receptor-binding protein (PA83), and the combination of PA with LF is
cytotoxic6. LF is a 91 kDa zinc metalloprotease that cleaves the N-terminal substrate docking
site of the mitogen-activated protein kinase kinases (MAP2K), preventing the passage of signals
in the ERK1/2, p38, and c-Jun N-terminal kinase pathways [7]. Intoxication of a cell begins
when PA83 binds to host cellular receptors, capillary morphogenesis protein 2 (CMG2), tumor
endothelial marker 8 (TEM8), or integrin beta 1 (ITGB1) [2,8,9]. Once bound, host furin cleaves
a 20 kDa fragment from the N-terminus of PA83, thus activating the 63 kDa protein, PA63 [10].
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Following activation, PA63 forms a heptamer and binds LF [11]. The toxin undergoes clathrinmediated endocytosis and a decrease in endosomal pH induces the formation of an endosomal
membrane PA channel, by which LF translocates into the cytosol [12] before PA pores are
transported to lysosomes for rapid degradation [8,13,14]. PA has been shown to induce the
process of autophagy, whereby autophagosomes encapsulate endosomes and facilitate the
delivery of LF into the cytoplasm [15]. A lysosomal protein, cathepsin B, is necessary for the
autophagic flux, whereby LF is delivered from the intralumenal vesicles of the autophagosomeencapsulated multivesicular late endosomes into the cytoplasm through a back fusion process
[14,16,17].
We observed that out of five compounds that inhibited anthrax and diphtheria toxins, two
compounds were structurally related 4-amino-quinolines, Chloroquine and Amodiaquine. Two
anti-malarial drugs, Chloroquine (CQ) and Amodiaquine (AQ), were observed to completely
protect host cells against anthrax toxin killing in 6-hours toxin killing assay (Fig. 2a). However,
our assay showed that unlike AQ, CQ only has a moderate ability to protect cells against LF-PA
mediated 24-hours killing (Fig. 2b). Interestingly, none of the other quinoline-containing
antimalarial compounds, Cinchonine, Primaquine, and Quinidine, from JHCCL were active
(Supplementary Fig. 1a–c).
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Figure 3.2: The anti-LF-PA efficacy of Amodiaquine (AQ) and its metabolite Desethylamodiaquine
(DEAQ) in intro and in vivo

Amodiaquine and JHCCL available structural analogs were tested for their ability to inhibit LF-PA-mediated cytotoxicity.
RAW264.7 cells were seeded at 1 × 104 cells/well on 96-well plates and the following day were incubated with indicated doses
of Amodiaquine or Chloroquine for 1 h, followed by either 6 h (a) or 24 h (b) intoxication with 500 ng/mL PA + 500 ng/mL LF.
Cell viability was determined by MTT assay (Materials and Methods) and is shown as the percentage of survivors relative to cells
not treated with drugs. AQ and DEAQ were tested for their ability to inhibit LF-PA-mediated toxicity in (c) RAW264.7 cells and
in (d) Sprague-Dawley rats. RAW264.7 cells were seeded at 1 × 104 cells/well on 96-well plates and the following day were
incubated with indicated doses of AQ or DEAQ for 1 h, followed by 6 h intoxication with 500 ng/mL PA + 500 ng/mL LF.
Survival curves of groups of male Sprague-Dawley rats challenged intravenously with 12 µg LF and 40 µg PA along with varying
amounts of AQ (1.5, 3.0, and 6.0 mg/kg). Control groups of rats either received toxin only or 6.0 mg/kg of AQ only.
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Amodiaquine and its metabolite are potent inhibitors of LF-PA induced death in vitro and in vivo
After oral administration, AQ is rapidly absorbed and undergoes fast and extensive
metabolisation by hepatocytes’ cytochrome p450 enzyme to the AQ metabolite, DesethylAmodiaquine (DEAQ), the main active metabolite of AQ [16]. We tested the ability of DEAQ to
reduce anthrax toxin mediated cellular killing, and we observed that just like AQ, DEAQ was
able to reduce toxin-mediated cytotoxicity with an EC50 of 5 µM (Fig. 2c). Since AQ and its
metabolite, DEAQ, protected host cells against anthrax toxin killing, we evaluated the efficacy of
AQ as a therapeutic agent during anthrax toxin intoxication in Sprague-Dawley rats. Animals
were injected intravenously with a lethal dose of anthrax toxin (LD100) and were intravenously
co-injected with AQ at 1.5, 3.0, or 6.0 mg/kg. The AQ doses were selected based on the FDA
approved AQ dose of 10 mg/kg [18]. Animals that received a lethal dose of anthrax toxin without
AQ all died within 90 minutes post intoxication (Fig. 2d). While the administration of AQ at
1.5 mg/kg saved 40% of the rats, all of the animals in that group displayed classical signs of
having undergone a toxin challenge, such as ataxia, lethargy, hyperpnea, and tachypnea. Rats
that were challenged with anthrax toxin and treated with AQ at 3.0 and 6.0 mg/kg all survived
without displaying toxin-associated symptoms (Fig. 2d).

Amodiaquine Inhibits Cytosolic Entry of LF
In order to identify the step at which AQ inhibits LF-PA-mediated lethality, we assessed
the processes that mediate the cellular entry of this toxin and toxin-induced pyroptosis in the
presence and in the absence of this drug. Caspase-1 activation, which occurs late in LF-PA
intoxication, was monitored using a fluorescent probe, FLICA. This probe specifically binds to
active caspase-1. While we observed high levels of caspase-1 activity upon LF-PA treatment in
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the absence of AQ, active caspase-1 was not detected in AQ-treated cells that were challenged
with anthrax toxin (Fig. 3a). This result shows that AQ inhibits cytotoxicity upstream of caspase1 activation.
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Figure 3.3: Amodiaquine inhibits cellular entry of LF

(a) AQ inhibits LT-mediated caspase-1 activation. RAW264.7 cells were seeded and allowed to adhere overnight, and then
incubated with 16 µM AQ or DMSO for 1 h before addition of 500 ng/mL PA + LF for 2 h. FLICA was added for a further 1 h
and then cells analyzed by fluorescence microscopy. (b) AQ inhibits LT-mediated cleavage of MEK-2. RAW264.7 cells were
incubated with AQ or DMSO for 1 h before addition of vehicle control or 1 µg/mL PA + LF for up to 2 h. Cells were lysed and
analyzed via immunoblotting with a MEK-2–specific antibody. Tubulin was used as a loading control. (c) FRET data showing
fluorescence emission from three reactions, where 5.8 µg/ml LF cleaves fluorescently labeled MAPKK peptide without drugs, in
the presence of a known LF inhibitor, 16 µM surfen hydrate, or in the presence of 16 µM AQ. (d and e) AQ protects cells from
PA + FP59. RAW264.7 cells were preincubated with a titration of AQ for 1 h, followed by a 6 h intoxication with 500 ng/mL
PA + LF (d) or FP59 (e). Cell viability was measured via MTT.
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Activation of caspase-1 by LF is a late step in pyroptosis and depends on LF catalytic
activity [19]. To determine whether AQ blocks proteolysis of cellular MAPKKs by LF, we
assessed the cleavage of MEK2 by immunobloting. While MEK2 was cleaved in LF-PA treated
RAW264.7 cells, treatment with AQ completely prevented this effect (Fig. 3b). These results
show that AQ inhibits either cytotoxicity upstream of MAPKK cleavage or blocks LF directly.
In order to test whether AQ inhibits the enzymatic activity of LF, we used a Fluorescence
Resonance Energy Transfer (FRET) based assay, in which an MEK2 peptide containing a
cleavage site for LF with a quenching DABCYL group at the N-terminus and FITC fluorogenic
group at the C-terminus was used as LF substrate for in vitro assays. After cleavage by LF, the
fluorescence emitted by the DABCYL increased (Fig. 3c). We tested the ability of AQ to inhibit
the proteolytic activity of LF at 16 µM using FRET. In the presence of a known small molecule
inhibitor of LF, surfen hydrate [20], no emission at 523 nm was seen (Fig. 3c). In the absence of
any chemical inhibitor, LF cleaved MAPKK peptide, and the fluorescence emission was
observed (Fig. 3c). A similar emission at 523 nm was observed when LF was able to cleave
MAPKK peptide in the presence of AQ, which shows that AQ does not block the proteolytic
activity of LF at 16 µM.
AQ-treated cells were found to be less sensitive to treatment with PA + FP59 (Fig. 3d,e).
FP59 is a hybrid toxin, which contains the PA binding site of LF as well as a toxin domain
derived from P. aeruginosa exotoxin A [21], that has been widely used as an LF surrogate, and
kills cells by a different mechanism [2]. This result, along with the caspase-1 and MEK2 data,
strongly suggest that AQ interferes with PA mediated toxin entry.
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Amodiaquine binds to and inhibits host cathepsin B
In order for LF to reach the cytosol, PA83 must bind to host cell receptors, be cleaved by
furin into PA63, heptamerize into a pre-pore form, bind LF, and proceed to low-pH endosomes
where PA-heptamers undergo an acid-dependent conformational change from pre-pore to pore
[22]. Host-cell binding of PA and its proteolytic cleavage were monitored by immunoblot in the
presence and in the absence of AQ. We observed that AQ did not block binding of PA83 to cells
or block proteolytic processing of PA to generate PA63 (Fig. 4a). The inability of AQ to block
the activity of host furin cleavage of PA83 is consistent with our observation that AQ equally
reduces sensitivity of host cells to both PA83 + LF and PA63 + LF treatments (Supplementary
Fig. 2). These results indicate that AQ blocks intoxication at a step downstream of PA binding
and assembly on the host-cell surface.
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Figure 3.4: Amodiaquine inhibits host cathepsin B

(a) AQ does not inhibit PA binding to RAW264.7 cells. Cells were incubated with AQ for 1 h at 4 °C before addition of
1 μg/mL PA for an additional 1 h. Cells were lysed and analyzed by immunoblotting with a PA-specific antibody. (b) AQ
neutralizes acidic vesicles. RAW264.7 cells were pre-treated with AQ or vehicle control for 1 h and then treated with
500 ng/ml of PA for an additional hour at 37 °C before addition of Lysosensor Green DND-189 for a further 10 min. Cells
were then visualized by fluorescence microscopy. (c) AQ results in increased abundance of PA pores. Cells were pretreated with AQ for 1 h at 37 °C and then were exposed to 1 μg/mL of PA at 37 °C for 1 h. Cells were lysed and analyzed by
immunoblotting with a PA-specific antibody. (d). FRET assay showing the activity of purified human cathepsin B without
drugs, or with addition of AQ, DEAQ, CQ, or DECQ at 4, 8, 16, 33, or 66 μM. (e) 1H-NMR spectra of AQ in the presence of
cathepsin B. The reference spectrum of AQ with its atoms labeled (top), and the STD spectrum (bottom) are shown. The
data were collected using a protein:ligand ratio of 1:100 with on- and off-resonance saturation at 0.04 ppm and 30 ppm,
respectively. (f) Chemical structure of AQ showing the atom-specific magnitude of the STD effects. The STD effect was
calculated according to the formula ASTD = (I0 − Isat)/I0. All STD effects are expressed as a percentage relative to the H4
atom (100%).
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CQ was previously shown to prevent endosomal acidification [23]. Since AQ is
structurally similar to CQ, we tested whether AQ neutralizes anthrax toxin induced endosomal
acidification. We used Lysosensor Green DND-189 to probe acidic organelles in the cells.
Lysosensor is a green fluorescent dye used for tracking acidic organelles in the cell.
Neutralization of these compartments can be visualized as a loss in punctate-fluorescent
structures. In the absence of AQ, PA-treated cells displayed Lysosensor fluorescence, and AQ
markedly decreased cell-associated Lysosensor fluorescence (Fig. 4b). These results predict that
AQ may block the ability of PA to either access acidified endosomes or to form PA pores. It is
known that the pore formation of PA, which results from exposure to acidic pH within
endosomes, is resistant to dissociation by SDS and runs as an oligomer on SDS-PAGE [22].
Surprisingly, treatment of cells with AQ resulted in higher, rather than lower, abundance of SDSresistant PA-oligomers compared to cells treated with PA only (Fig. 4c).
A similar observation was reported by Ha et al.14, who showed that an inhibition of host
lysosomal cathepsin B by an unrelated small molecule CA-074, resulted in (i) elevated
accumulation of PA pores in late endosomes, (ii) the inability of LF to be released from the late
endosomes into the cytoplasm, and (iii) results in reduction of cellular sensitivity to LF-PA.
Upon formation of the SDS-resistant PA63 pore in acidic endosomes, PA pores are then
transported to lysosomes for rapid degradation24. Ha et al. showed that cathepsin B mediates the
fusion of lysosomes with endosomes, and that this fusion is necessary for the release of LF from
the endosomes into the cytoplasm14. In order to gain further insight into the mechanism of AQmediated protection of cells against anthrax toxin killing, we tested whether AQ inhibits
cathepsin B protease activity of purified human cathepsin B using a FRET assay. We observed
that both AQ and DEAQ directly inhibit cathepsin B activity in a dose dependent manner
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without drug pre-incubations, at drug concentrations used in cellular experiments (Fig. 4d). We
tested whether AQ inhibits cathepsin B in RAW264.7 cells. We observed that cells pre-treated
with AQ or with DEAQ for 1 hour lost cathepsin B enzymatic activity in a dose dependent
manner (Supplementary Fig. 3a). In addition, we tested the ability to AQ to inhibit cathepsin B
activity in a protein lysate from cells that were not exposed to drugs prior to the lysis, and we
observed that AQ and DEAQ inhibited cathepsin B activity (Supplementary Fig. 3b). We
determined that the addition of drugs to cathepsin B reactions did not change the pH (pH 5.8) of
the reaction buffer. In all of the cathepsin B experiments we observed that CQ and its metabolite,
Desethyl-Chloroquine (DECQ), were weaker inhibitors of cathepsin B activity (Fig. 4d and
Figure S3), which corresponds to the phenotypic data seen in Fig. 2.
The interaction between AQ and cathepsin B was probed using saturation transfer
difference NMR spectroscopy (STD). This technique is a powerful label-free ligand-observed
tool to study molecular interactions in solution [25,26]. STD relies on the transfer of selective
saturation (excitation) of the protein’s atoms to atoms located in the bound ligand. Two 1D 1HNMR spectra are acquired—one in which the protein’s signals are selectively saturated (“on”
resonance, Isat), and another in which no signals are saturated (“off” resonance, I0). Ligand
binding is evident by the difference spectrum (I0 − Isat), as only when binding occurs are the
signals of the ligand affected. Figure 4e shows the 1H-NMR spectrum of 2 mM AQ in the
presence of 20 µM cathepsin B (ligand:protein molar ratio of 100:1), and its corresponding STD
difference spectrum. The presence of AQ signals in the difference spectrum clearly indicates that
it is binding to the enzyme. An inspection of the atom-specific effects provides insight into the
mode of binding. Atoms in the quinoline backbone display the largest reduction in their
intensities, suggesting that they are in close proximity to cathepsin B (Fig. 4f, atoms H4 and H5
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exhibit STD effects of 100 and 97%, respectively). In contrast, the H9 and H10 methylene
protons are modestly affected, suggesting that in the complex they are located distal to hydrogen
atoms in the protein. Interestingly, several atoms in the phenol ring display substantial STD
effects suggesting that they are near the protein. This is consistent with the lower biological
activities of AQ analogs that remove the phenol ring (Fig. 2 and Supplementary Fig. 1). The
importance of the AQ quinoline ring revealed by STD is also compatible with the crystal
structure of cathepsin B bound to nitroxoline, as this small molecule contains a quinoline moiety
that interacts extensively with the enzyme [27].

Amodiaquine inhibits pathogenicity of Ebola virus
Upon observing that AQ protects cells from anthrax and diphtheria toxins, we
hypothesized that AQ and DEAQ might also be able to inhibit the entry of Ebola virus. Ebola
virus, among other viruses, requires low endosomal pH [28] as well as host cathepsin B function
[29] for membrane fusion and infection of host cells. In fact, AQ and CQ have recently been
reported to inhibit Ebola virus pathogenicity in cells [28,29]. We re-tested AQ and CQ’s ability
to inhibit Ebola virus abundance in infected HeLa cells by visualizing infected cells using
immune-staining, and in addition we tested the ability of their metabolites, DEAQ and DECQ, to
inhibit Eboa virus propagation in cultured cells in vitro. To test AQ-mediated inhibition of viral
propagation, we compared infection by Ebola virus (Kikwit) at MOI of 0.5 with and without
drugs for 48 hours. To detect infected cells, immuno-staining was completed with anti-Ebolaglycoprotein antibodies. AQ and DEAQ effectively inhibited propagation of Ebola virus in HeLa
cells with EC50’s in the low µM range (Table 1): the EC50’s of AQ and DEAQ were 3.8 and
3.6 µM respectively. The EC50’s of CQ and DECQ in HeLa were 4.8 and 7.3 µM respectively.
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This data shows that DEAQ is more efficacious in inhibiting Ebola propagation compared to
DECQ. Similar results were obtained by testing AQ, CQ, DEAQ, and DECQ for their ability to
inhibit Ebola virus in primary human cell line, HFF-1 (Supplementary Table 1). This result
confirms that anti-viral effect of AQ is not related to its effects on the host cell cycle or cellular
proliferation.
Table 3.1: The effect of AQ, CQ, and its metabolites, DEAQ and DECQ, on the pathogenicity of
EBOV in HeLa cells
Pathogen
EBOV
EBOV
EBOV
EBOV

Drug, hours
AQ, 48 h
DEAQ, 48 h
CQ, 48 h
DECQ, 48 h

EC50
µM
3.8
3.6
4.8
7.3

SD
µM
0.38
0.35
0.57
0.55

CC50
µM
50
50
100
100

SI50
13.2
13.9
20.7
13.8

The ability of drugs to reduce the abundance of Ebola virus (EBOV) in host cells was measured in cells by fluorescent
microscopy.

The life cycle of Ebola virus in cultured host cells is 20–24 hours. To more clearly
evaluate effects of AQ and DEAQ on a single viral life cycle, we compared the inhibitory effects
of these drugs after 24 and 48 hours of Ebola virus infection in cells. We observed that AQ and
DEAQ are at least two times more potent after 24 h of infection (EC50’s 2 µM), compared to
48 h, during which time the secondary round of infection occurs and possibly slightly decreases
the antiviral efficacies of AQ and DEAQ (EC50’s 4 µM) (Table 2).
Table 3.2: The effect of time of AQ and its metabolite treatments on the pathogenicity of EBOV.
Pathogen
EBOV
EBOV
EBOV
EBOV

Drug, hours
AQ, 24 h
AQ, 48 h
DEAQ, 24 h
DEAQ, 48 h

EC50
μM
2.38
4.46
2.15
4.12

SD
μM
0.47
0.44
0.48
0.36

CC50
μM
>50
>50
>50
>50

SI50
>21
>11.2
>23.3
>12.1

The 50% effective (EC50, virus-inhibitory) concentrations and 50% cytotoxic (CC50, cell-inhibitory) concentrations were
determined. CC50 divided by EC50 indicate the selectivity index (SI) value.
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Amodiaquine inhibits pathogenicity of other Category A, B, and C pathogenic agents that enter
into host cytoplasm from acidified endosomes
In addition to anthrax toxin [15], diphtheria toxin [30], and Ebola virus29,31, other
pathogenic agents SARS coronavirus [31], Venezuelan equine encephalitis virus (VEEV) [32],
Rabies virus [33], Junin virus [34], Chikungunya virus [35], and Clostridium difficile toxin B
[36] enter the cytoplasm from endosomes and all require the acidification of endosomes. We
demonstrated that all of those pathogenic agents are inhibited by AQ in their respective in vitro
cellular assays (Table 3 and Supplementary Fig. 4a). We also tested the ability of DEAQ to
inhibit pathogenicity of Junin and Chikungunya viruses, and observed that DEAQ inhibits those
two viruses with EC50’s similar to those of AQ (Supplementary Table 2).
Table 3.3 Sensitivities of Category A, B, and C pathogens to Amodiaquine
Pathogen
EC50 µM
CC50 µM SI50
Pathogens known to enter into cytoplasm from Endosomes, low pH-dependent
Ebola Virus
2.4
>50
>20
SARS coronavirus
2.4
32
13.3
Venezuelan equine encephalitis virus
3.2
31
9.7
Rabies
5.7
>10
>2
Junin
16.9
50
3.0
Chikungunya
18.3
>50
>2
Clostridium difficile Toxin B
4.6
30.7
6.7
Entry into cytoplasm from Endoplasmic Reticulum
Poliovirus 3
>100
>100
1
Herpes simplex virus 1
>60
>60
1
Cholera Toxin
>66.7
>66.7
1
Pseudomonas aeruginosa Exotoxin A
>66.7
>66.7
1
Pathogens known to enter into cytoplasm, low pH-independent
Human Cytomegalovirus
>60
>60
1
Respiratory syncytial virus
32
32
1
The ability of drugs to reduce the abundance of the indicated pathogens viruses or cytotoxicity induced by bacteria toxins in host
cells. The analysis was done as in Table 1.

Other pathogenic agents, including cholera toxin [37], Pseudomonas aeruginosa exotoxin
A38, Poliovirus 3 [18], and Herpes simplex virus 1 [39] are transported in a retrograde fashion to
the endoplasmic reticulum (ER) and retrotranslocated into the cytoplasm by the host ERassociated degradation pathway [37,38]. We observed that cytotoxicity mediated by those
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pathogens was not blocked by AQ (Table 3 and Supplementary Fig. 4b,c). In addition, the
inability of AQ to inhibit cholera and Pseudomonas toxins, which are both ADPrybosyltransferases, suggests that AQ’s adverse effect on diphtheria toxin (Fig. 1), which is also
ADP-rybosyltransferase, occurs by inhibition of host cathepsin B only.
Another group of pathogens enter the cytoplasm by ways that do not rely on the
acidification of endosomes, and include Human Cytomegalovirus [40] and Respiratory syncytial
virus [41]. We determined that AQ did not reduce the pathogenicity of those viruses (Table 3).
This data supports the conclusion that AQ inhibits the entry of toxins into the cytoplasm from
acidified endosomes.

Discussion
The discovery and development of novel drugs against biological threat agents such as
Bacillus anthracis and Ebola virus, is an important concern worldwide. We have shown that AQ
is a broad-spectrum drug that could be applied rapidly to cure biological emergencies caused by
the several identified pathogens (Fig. 5). For example, the current Ebola crisis has already killed
more than 10,000 people in 2014 and 2015. Repurposing of a compound with well-established
safety and pharmacokinetic profiles—as well as proven high-volume GMP manufacturing—may
be the only way that a therapy can be tested and deployed in time to protect the 21 + million
people in the three hardest-hit West African countries.
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Figure 3.5: Mechanism of action of Amodiaquine

AQ reduces the activities of pathogens that enter into host cytoplasm from acidified endosomes by exploiting cellular
cathepsin B. AQ does not inhibit the entry of pathogens that enter through a retrograde fashion to the endoplasmic
reticulum (ER) and retrotranslocated into the cytoplasm by the host ER-associated degradation pathway or by pHindependent entry into cytoplasm.

To help address this Ebola crisis, as we were preparing this manuscript, we
communicated our discoveries to Médecins Sans Frontières (MSF, Doctors Without Borders),
and encouraged them to explore whether the administration of AQ in West African countries hit
by Ebola epidemic is associated with a reduced mortality due to Ebola infections. MSF
conducted a study and observed that the administration of AQ provided a substantial protection
against Ebola mortality and reduced the mortality risk by 31%, and in this study MSF
acknowledged the authors of this study (https://www.youtube.com/watch?v=rTyoc4s1Mco).
As seen in current Ebola epidemic, the human host can be co-exposed to numerous
deadly pathogens and thus the infected individual will need to take numerous countermeasures
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(each with their own side-effects) to protect against multiple infectious organisms. Therefore,
therapies capable of inhibiting multiple pathogens are needed. Broad-spectrum anti-pathogen
drugs, capable of simultaneously inhibiting numerous unrelated pathogens, could be developed
by targeting host proteins commonly exploited by those pathogens. In this work we show that
AQ inhibits the host target rather than the pathogen, which makes AQ host-oriented broadspectrum antimicrobial that is less likely to be circumvented by pathogen mutations that lead to
microbial resistance to the countermeasure.
AQ was discovered by Parke-Davis in the 1940s and was approved by the FDA as an
anti-malarial in the late 1940s and early 1950s under the trade name Camoquine. AQ is currently
on the WHO’s Model List of Essential Medicines. Today AQ is recommended as a frontline antimalarial therapy in combination with artemisinin. AQ belongs to the “quinoline antimalarials”
(Reviewed

in

[42]).

AQ

inhibits

Plasmodium

falciparum

phosphoethanolamine

methyltransferase, an enzyme found in malarial parasites but not in humans [43]. Here we report
that AQ also binds and blocks the function of host cathepsin B protein and thus entry of key
pathogens into the cytoplasm.
Since AQ has been used for the past 60 years, its safety and pharmacokinetic profiles are
well known. For example, it has been determined that after oral administration in healthy
subjects, AQ is quickly absorbed and biotransformed into its main active form, DEAQ, which in
turn is slowly eliminated with a terminal half-life of 9–18 days. The availability of PK values for
AQ allows us to compare it to our in vitro data. The EC50 values for all of the tested pathogens
inhibited by AQ or by DEAQ were at low µM range. Importantly, the known Cmax values
(maximal amounts of drug in the blood after oral administration) of DEAQ in humans are in low
µM range [43,44,45] and are comparable to the DEAQ EC50 values found in vitro for tested
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pathogens. This suggests that it is possible to achieve anti-pathogen effective AQ doses in blood
by orally administered AQ.

Methods
Chemicals and Reagents
All toxins were purchased from List Biological Laboratories. FP59 was a kind gift from
S. Leppla (National Institute of Allergy and Infectious Diseases/National Institutes of Health,
Bethesda, MD). An FDA-approved drug library comprising of 1,581 drugs was purchased from
Johns Hopkins, titled, Johns Hopkins Clinical Compound Library (JHCCL) version 1.0. The
drugs arrived as 10 mM stock solutions in sealed microtiter plates and were made using DMSO
or water as solvents. Drugs were arrayed in 96-well plates and screened at a stock concentration
of 10 mM. The library was stored at −20 °C until use. Prior to use, the library of drugs was
thawed at 25 °C. Compounds that were determined to be compounds of interest, were isolated
and reproduced from 10 mM solutions. Amodiaquine, Chloroquine, Cinchonine, Primaquine, and
Quinidine were purchased from Sigma-Aldrich (St. Louis, MO, USA). All drugs were prepared
at 10 mM using DMSO as a solvent. Desethyl-amodiaquine and desethyl-chloroquine were
purchased from Toronto Research Chemicals Inc. Anti–N-terminal MEK-2, anti-tubulin, and
anti-PA antibodies were purchased from Santa Cruz Biotechnology. Purified human cathepsin B
protein used for NMR experiments was purchased from ACROBiosystems.

Cellular Drug Screens
RAW264.7-pGIPZ(−)2 mouse macrophage cells were maintained in DMEM (SigmaAldrich) supplemented with 10% FBS (Bioexpress) and 100 µg/mL penicillin and 100 µg/mL
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streptomycin. RAW264.7-pGIPZ(−) cells (10,000 per well) were seeded in 96-well plates
(100 µl/well) 24 hours before the assay. During the drug library screen assay, 0.75 µl of 3.3 mM
drugs were added to 150 µl of cell-containing media to achieve 16 µM of each compound per
well. Cells were treated with compounds for 1 hour at 37 °C 5% CO2, and then challenged with
anthrax toxins, such that the final toxins concentrations were 0.5 µg/ml. Cells were treated with
toxin and drugs for 6 hours. As rodent cells are resistant to diphtheria toxin, C32 human
melanoma cell line was used for diphtheria toxin screening, where cells were treated with
2 µg/ml for 24 hours. Determination of cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay was performed as described [46]. Cell viability is
shown as the percentage of surviving cells obtained relative to cells treated with DMSO (100%).

FRET MAPKKide LF activity
For drug testing in 96-well plates, the reaction volume was 250 µl per well, containing
20 mM HEPES pH 7.2, 5 µM MAPKKide conjugated with DABYL and FITC (List Biological
Laboratories, Inc), and 3.3 µM of JHCCL compound. The reaction was initiated by adding LF to
a final concentration of 6 µg/ml. Kinetic measurements were obtained at 37 ºC every 40 sec for
40 min using a fluorescent plate reader. Excitation and emission wavelengths were 490 nm and
523 nm, respectively, with a cutoff wavelength of 495 nm.

Toxin Treatments
Cells were seeded in a 96-well plate at a density of 10,000 cells/well 1 d before toxin
treatment. Various concentrations of LF or FP59 combined with a fixed concentration of PA
(500 ng/mL) were added to the wells, and cells were incubated for 6 h at 37 °C. Cell viability was
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measured by MTT assay. In other toxin treatment experiments, cells were pre-treated with
various concentrations of drugs, and then treated with constant concentrations of 8.3 µg/ml of C.
difficile toxin B, 500 ng/ml of P. aeruginosa Exotoxin A, or 500 ng/ml of Cholera toxin for
6 hours. RAW264.7 survival was measured by MTT assay. Each data point shown for MTT
assays indicates the mean ± SD value obtained in triplicate assays done in a representative
experiment. At least three such experiments were routinely carried out.

MEK Cleavage Assay
RAW264.7 cells were pre-treated with 66.67 mM of AQ for 1 hour. Following the pretreatment, the cells exposed to 1 mg/mL of PA and LF at 37 °C for up to two hours in the
presence of 16.67 µM of AQ. The cells were then washed with cold PBS for 5× and lysed with
RIPA buffer containing a protease inhibitor mixture (Roche). Cell lysates were quantified using
the BCA protein quantification kit (Pierce) and loaded onto 4–12% denaturing gels (Criterion
XT Precast Gel, Bio-Rad). After electrophoresis for several hours, the gel was transferred
overnight to nitrocellulose membranes; membranes were probed with anti-MEK-2 or anti tubulin
antibodies. Quantitative Western blot analyses of the bands were accomplished using the
VersaDoc 1000 instrument (Bio-Rad) or Odyssey infrared imaging system (LI-COR
Biosciences).

Biochemical Assay of PA Binding and Internalization
Cells were pre-treated with AQ as described above for 1 h, either at 4 °C for PA binding
or at 37 °C for PA internalization assays cells were exposed to 1 µg/mL of PA at 4 °C for 1 h for
binding assay or at 37 °C for 1 h for internalization assay. Cells were then washed with PBS
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solution three times and lysed in RIPA buffer containing a protease inhibitor mixture (Roche).
Western blot analysis was performed using anti-PA antibody anti-tubulin monoclonal antibody
(Sigma-Aldrich). Chemiluminescence of bands and their relative intensities were revealed using
a VersaDoc 1000 instrument (Bio-Rad).

Caspase-1 Activity Assay
Cells were treated with AQ for 1 h before addition of 500 ng/ml LF-PA for an additional
2 h. FAM FLICA™ Caspase 1 Assay Kit was obtained from ImmunoChemistry Technologies
LLC. FLICA reagent was added for 1 h. FLICA fluorescence was visualized as follows: cells
were washed three times in PBS, fixed in 4% (wt/vol) paraformaldehyde, and examined under a
fluorescence microscope (DM5500 B; Leica).

Staining Cells with Lysosensor Green DND-189
Cells were treated with AQ for 1 h before an addition of 500 ng/ml PA for an additional
hour and then stained with Lysosensor Green DND-189 for 10 min at 37 °C. Cells were then
washed and fluorescence was visualized as follows: cells were fixed in 4% (wt/vol)
paraformaldehyde, and examined under a fluorescence microscope (DM5500 B; Leica).

Cathepsin B Activity Assay
Cathepsin B activity in total cell lysates was determined using an InnoZyme ™ cathepsin
B activity assay kit (EMD Milipore) and performed according to the manufacturer’s instruction.
Cathepsin B activity in cellular lysates was tested in the following way: RAW264.7 cells
untreated with drugs were lysed, and equal amount of cathepsin B containing protein lysate was
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added to the substrate solution (EMD Milipore) with and without AQ, CQ, DEAQ, or DECQ at
concentrations of 4, 8, 16, 33, or 66 µM. Cellular cathepsin B activity with and without drugs
was tested by pre-treating cells with drugs for 1 hour, followed by lysing cells and testing
cathepsin B activity with a fluorescently labeled substrate. The activity of 0.5 ng/µl of purified
human cathepsin B was mixed with and without drugs without pre-incubation and detected with
a fluorescently labeled substrate. Fluorescence intensity indicating cathepsin B activity was
measured at an excitation wavelength of 370 nm and emission wavelength of 450 nm (Molecular
Devices, Spectra Max 384 PLUS).

Rat intoxication challenge
The rat studies were performed at Explora Biolabs, San Diego, CA following Institutional
Animal Care and Use Committee (IACUC) approved protocols. Five Male Sprague-Dawley rats
(226 to 250 g; Charles River) per group were used. The toxin mixture was prepared for each
group by mixing 12 µg of LF with 40 µg of PA or with 1.5, 3.0, or 6.0 mg/kg of Amodiaquine in
a 500-µl volume per rat. Rats were monitored for signs of clinical illness or death for 14 days
after the challenge.

NMR spectroscopy
All STD experiments were performed at 25 °C using a Bruker Avance 500-MHz
spectrometer equipped with a cryogenic probe. The pulse scheme employed excitation sculpting
with gradients, and a 50 ms spin lock filter (T1ρ) to suppress signals originating from the water
and protein signals, respectively [25]. An irradiation power of 26 Hz was applied on-resonance at
0.04 ppm, and off-resonance at 30 ppm, for a total saturation time of 4 s. Spectra were collected
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in an interleaved manner to account for any temporal fluctuations. Separate control experiments
were performed using samples of cathepsin B or Amodiaquine to confirm the selectivity of
saturation. STD spectra were acquired with 4096 scans and 32 k data points using a spectral
width of 7002.8 Hz centered at 2352 Hz. All experiments were performed in deuterated tris
buffer: 50 mM D11-Tris, 150 mM NaCl, pH 7.5 supplemented with 8% D2O. The sample used
for STD measurements contained 20 mM and 2 mM cathepsin B and Amodiaquine, respectively.
The STD NMR data were processed and analyzed using Topspin 3.1 software (Bruker, Billerica
Ma). STD effects were calculated according to the formula: ASTD = (I0 − Isat)/I0, where Isat
and I0 are the intensity of the Amodiaquine signal recorded with and without saturation of the
protein, respectively.

Viral tests
The procedures of all viral experiments are described in supplemental materials and
methods. Specifically, infection of HeLa cells with Ebola was done using Ebola virus (Kikwit)
MOI = 0.5 (calculated for 4,000 cells/well, assuming one complete round of replication of HeLa
cells at 15 ± 2 hrs after cell seeding). Cells were incubated with the virus for 24 or 48 h. Infection
was terminated by fixing samples in formalin solution, and immuno-staining was used to
visualize infected cells. Cells were treated with anti-GP specific monoclonal antibody (6D8) (1
to 1000 dilution) followed by anti-mouse IgG conjugated with Dylight488 (Thermo) (1 to 1000
dilution) in blocking buffer containing 3% BSA in PBS. Nuclei were stained with Draq5
(Biostatus) diluted in PBS buffer. Images were acquired on the Opera imaging instrument
(Perkin Elmer) using 10× Air objective and four images/well were acquired and analyzed using
PE Acapella algorithms.
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Transition
The previous chapter described our first attempt to identify a host-oriented
therapy using a similar yet disparate toxin screen method. Our findings identified
Amodiaquine as a successful host protein inhibitor of Cathepsin B, necessary for
authophagic flux. In addition, we showed that Amodiquine could act as a broadspectrum therapy for other pathogenic agents that utilize the same host protein,
such as Ebola virus. However, we realized that we would need to optimize our
methods in order to guarantee host-oriented drug hits. In the following chapter we
describe multiplex drug screens that involved the simultaneous screens against
three toxins (cellular toxin challenge) that cause an increase in caspases (signals
leading to programmed cell death) as well as direct screens against caspases
themselves (FRET).
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Bithionol blocks pathogenicity of bacterial toxins, ricin, and Zika virus
William Leonardi, Leeor Zilbermintz, Luisa W. Cheng, Josue Zozaya, Sharon H. Tran, Jeffrey H.
Elliott, Kseniya Polukhina, Robert Manasherob, Amy Li, Xiaoli Chi, Dima Gharaibeh, Tara
Kenny, Rouzbeh Zamani, Veronica Soloveva, Andrew D. Haddow, Farooq Nasar, Sina Bavari,
Michael C. Bassik, Stanley N. Cohen, Anastasia Levitin & Mikhail Martchenko

Abstract
Diverse pathogenic agents often utilize overlapping host networks, and hub proteins
within these networks represent attractive targets for broad-spectrum drugs. Using bacterial
toxins, we describe a new approach for discovering broad-spectrum therapies capable of
inhibiting host proteins that mediate multiple pathogenic pathways. This approach can be widely
used, as it combines genetic-based target identification with cell survival-based and protein
function-based multiplex drug screens, and concurrently discovers therapeutic compounds and
their protein targets. Using B-lymphoblastoid cells derived from the HapMap Project cohort of
persons of African, European, and Asian ancestry we identified host caspases as hub proteins
that mediate the lethality of multiple pathogenic agents. We discovered that an approved drug,
Bithionol, inhibits host caspases and also reduces the detrimental effects of anthrax lethal toxin,
diphtheria toxin, cholera toxin, Pseudomonas aeruginosa exotoxin A, Botulinum neurotoxin,
ricin, and Zika virus. Our study reveals the practicality of identifying host proteins that mediate
multiple disease pathways and discovering broad-spectrum therapies that target these hub
proteins.
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Introduction
In recent years, a better understanding of protein interaction networks has led to the
identification of highly connected hub proteins and pathways that are commonly used by a
number of different pathogens and in a range of diseases [1]. These hubs represent promising
targets for drug development.
Most disease networks have the “small-world” property, where proteins are only a few
interactions away from any other proteins [2]. Therefore, inhibiting a given node can potentially
affect the state of most nodes in its vicinity as well as the activity of the network itself. In this
way, therapeutic inhibition of nodes and hubs within one disease network can affect other
disease modules or pathways. Here we develop an approach to systematically identify broadspectrum drugs that target proteins exploited by multiple human disease pathways (Fig. 1a).
Frequently, multiple infectious pathogens or toxins that negatively affect hosts by different
mechanisms exploit the same host pathways [3]. This notion raises the prospect that multiplex
approaches may lead to the discovery of broadly active and host-oriented infectious disease
countermeasures that target host functions exploited by multiple pathogenic agents. We use
genetics and a new drug screening methodology to identify and characterize the previously
approved drug Bithionol as an inhibitor of host caspases, which reduces pathogenicity of a wide
range of pathogenic agents, including ricin, anthrax lethal toxin, Botulinum neurotoxin A,
diphtheria toxin, Pseudomonas aeruginosa exotoxin A, cholera toxin, and Zika virus.
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Figure 4.1: Inhibitors of hubs of human disease networks

(a) Depiction of the concept where multiple pathogenic pathways overlap, and hub proteins (blue circles) mediate multiple
disease pathways. This model proposes a drug screen design to look for compounds that simultaneously inhibit the function of
the hub proteins and reduce cellular lethality caused by multiple pathogenic pathways. (b) A depiction of the design of the
current study. The known host pathways and host proteins exploited by pathogens (HPEP) are considered. HapMap cell lines are
used to study the association between cellular sensitivity to Pseudomonas aeruginosa exotoxin A (PE) and genetic mutations in
genes coding for proteins exploited by PE. Mutations in host caspases are associated with altered sensitivity to PE, and these
proteins are defined as disease network hubs, which will be used as targets for the following drug screens. This approach yields
the broad-spectrum, host-oriented drug, Bithionol.
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Results
Identifcation of host hub proteins exploited by multiple pathogenic toxins.
Cytotoxic bacterial and plant toxins have evolved to exploit host proteins and cellular
pathways that mediate the entry of those toxins into host cells and to induce cell-death. Although
toxins exploit unique host pathways, these pathways are interconnected. While anthrax,
diphtheria, and Botulinum toxins reach the cytoplasm from acidified endosomes, cholera,
Pseudomonas aeruginosa and ricin toxins are transported into the cytoplasm through the host
ER-associated degradation pathway [4]. These pathways interconnect at host “hub” proteins.
Using one of those toxins, Pseudomonas aeruginosa exotoxin A (PE), we set out to identify such
hub proteins by i) determining whether known genetic mutations in host proteins exploited by PE
a affect the sensitivity of host cells to this toxin, and ii) investigating whether these host proteins
are also exploited by additional pathogenic agents. The protein hubs will be used as targets in
drug screens in order to discover broad-spectrum, host-oriented, anti-pathogenic agent drugs
(Fig. 1b).

The effect of caspase mutations on the sensitivity of human B-cells to P. aeruginosa exotoxin A
It has previously been shown that PE exploits several host proteins for its binding to and
entry into host cells [5] and initiates programmed cell death by inducing activities of host
caspase-3, -6, and -7 [6]. We investigated whether known mutations in host proteins exploited by
PE associate with altered cytotoxicity of the toxin in cells from tissues that are naturally attacked
by this toxin. The availability of human B-cells, which are physiological targets of PE [7]
through the HapMap Project [8] has provided us with an opportunity to test whether mutations in
host proteins that constitute the PE pathogenicity pathway affect the cellular sensitivity to this
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toxin. Our initial tests with cells from a few individuals revealed that their sensitivity to PE
varies greatly. Remarkably, our further investigation of PE sensitivity of B-lymphoblastoid cells
derived from 234 individuals in geographically and ethnically diverse human populations [87
Yoruba in Ibadan, Nigeria (YRI), 60 Utah residents with ancestry from northern and western
Europe (CEU), 43 Japanese in Tokyo, Japan (JPT), and 44 Han Chinese in Beijing, China
(CHB)] showed a prominent 200-fold difference in lethality to the toxin (Fig. 2a,b). The range in
PE sensitivity, as measured by the dose required to kill 20% of the cells [log(1/LD20)], was
similar in all four human cell populations (Fig. 2c). Analysis of toxin sensitivity in
parent/children trios indicated that relative sensitivity to PE is a heritable trait (P-value <0.0001)
(Fig. 2d).
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Figure 4.2: The effect of Bithionol on P. aeruginosa exotoxin A in human B-lymphoblastoid cells

(a,b) Human lymphoblastoid cells sensitivity to P. aeruginosa exotoxin A (PE)-mediated toxicity. (a) 234 B-lymphocytes were
treated with PE at concentrations shown. Cell viability was determined by Alamar Blue assay (Materials and Methods) and is
shown as the percentage of survivors relative to cells treated with PE alone. The LD20 calculation for the most sensitive cell line
is shown as an example. (b) LD20 values (ng/ml of PE) were calculated and expressed on an inverse log10 scale. For
calculations, PE sensitivity is defined numerically as 1/LD20. (c) Population-specific distribution of toxins sensitivities. CEU,
YRI, JPT, and CHB denote European, Yoruba, Japanese, and Chinese Han, respectively. One CHB outlier is excluded. For each
population, the black bar represents the median log sensitivity; the box extends from the lower to the upper quartile and the
whiskers extend to the most extreme data point. (d) Heritability of log sensitivity in Yoruba trios. Plot of the log toxin sensitivity
of the children against the mean log toxin sensitivity of the parents. The heritability is estimated as the slope (0.74) of the
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regression of the children phenotype on the midparent phenotype. (e) In CEU caspase-7 SNP rs3814231 associates with log PE
sensitivity.

The widespread and unimodal distribution observed for log(1/LD20) (Fig. 2b) is likely a
result of a polygenic inheritance model, consistent with evidence that multiple host proteins
mediate PE lethality [5,6]. To learn whether genetic variations in the genes encoding for these
proteins account for any of the variation in sensitivity of B-cells to PE seen in Fig. 2a, we tested
the association of numerous previously reported mutations with PE sensitivity. Caspase-7 and -3
mutations that were previously reported to associate with cancer and rheumatoid arthritis
[9,10,11,12,13] demonstrated a significant association with PE sensitivity in the individual
HapMap populations (CASP7, rs3814231, CEU, P = 0.01; CASP7, rs2227309, CEU, P = 0.02;
CASP3, rs4647601, rs4647693, and rs1049216, East Asian populations CHB and JPT combined,
P = 0.04 for each SNP) (Figs 2e and S1). These results show that the activity of caspases affects
host cell sensitivity to toxins, and that these proteins are potential therapeutic intervention points
and targets for the following drug screens. In addition to PE, ricin and toxins of anthrax,
diphtheria, Botulinum, and cholera induce programmed cellular death by activating host caspases
[6,14,15,16,17,18,19,20] (Fig. 3a). Therefore, a drug screen against hub caspases is of great
interest, as these proteins are exploited by multiple pathogenic pathways, and caspase inhibitors
can act as broad-spectrum drugs.
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Figure 4.3: The use of the Clinical Compound Library (CCL) to screen for inhibitors of hubs of
human disease networks

(a) Depiction of toxins as well as their pathways that induce caspase-mediated cell death. These toxins enter into host cytoplasm
either from acidified endosomes or endoplasmic reticulum. Broad-spectrum anti-toxin drugs are screened to identify inhibitors of
host caspases. (b) Overall approach scheme: CCL is screened by a multiplex approach that incorporates biochemical FRET and
cell survival assays looking for drugs capable of simultaneously inhibiting host caspases-3/6/7 and reducing cytotoxicities of
three bacterial toxins. The output of this approach is the discovery of broad-spectrum and host-oriented drug, Bithionol. (c)
Schematic diagram of cellular screens to identify drugs that reduce cellular lethality induced by diphtheria toxin, Pseudomonas
aeruginosa exotoxin A, and cholera toxin. Numbers are the distribution of inhibitors obtained in all screens. (d) Schematic
diagram of parallel FRET screens to identify drugs that inhibit proteolytic reaction of caspases-3, -6, and -7.
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A multiplexed cellular screen for CCL drugs that inhibit cytotoxic activities of bacterial toxins
exploiting unique but interconnected host pathways
In an effort to identify existing drugs that might be repurposed as novel, host-oriented,
broad-spectrum therapies, we screened a Clinical Compound Library (CCL)21 through
multiplex-based drug screening (Fig. 3b). We searched for compounds capable of both (i)
reducing cytotoxicities of diphtheria toxin, cholera toxin, and PE, and (ii) inhibiting proteolytic
activities of host caspases-3, -6, and -7 exploited by these toxins in biochemical assays (Fig. 3b–
d). In principle, a combination of biochemical and cellular drug screens could provide drug hits
that reduce toxins’ cytotoxicities by inhibiting host caspases, and thus, this approach could
simultaneously provide drug candidates and their protein targets.
We screened members of the CCL for the ability to reduce cell death of host RAW264.7
and C32 cells treated with PE, cholera toxin, or diphtheria toxin (Fig. 3c). At the indicated doses,
between 30 and 50 percent of RAW264.7 cells undergo cell death within 12 hours for
Pseudomonas and cholera toxins. For C32 cells, similar cell death was observed at 24 hours of
exposure to diphtheria toxin under the experimental conditions employed. A “hit” in our screen
was defined as an event where cells exposed to a drug increased cell survival by at least 20
standard deviations (~1% hit rate) above the survival of control cells treated with either toxin,
and is not cytotoxic to cells in the absence of toxins. Events defined as “multiplex hits”
interfered with cell killing by at least two toxins. The two multiplex hits that were identified as
capable of reducing the cytotoxicities of all three toxins were Bithionol and Pyrogallol (Fig. 3b).
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A multiplex protein function-based screen for CCL drugs that inhibit proteolytic activities of host
caspase-3, -6, and -7
In parallel experiments, we screened the CCL for drugs that could inhibit the function of
hub caspases-3, -6, and -7 (Fig. 3d) that mediate cytotoxicity caused by bacterial toxins used in
our multiplex cellular drug screens (Fig. 3b). Caspase activities were induced in RAW264.7 cells
by PE treatment. To screen and identify drugs that inhibit proteolytic activities of caspases we
utilized a fluorescence-based FRET assay. Optimized substrate peptides for caspase-3, -6, and 3/7 proteolytic activities were used with a fluorogenic 7-amino-4-methylcoumarin group at the
N-terminus and acetyl quenching group at the C-terminus. As a FRET substrate that is uniquely
cleaved by caspase-7 hasn’t been identified, and since caspases-3 and -7 are close orthologues,
we searched for caspase-7 inhibitors that could block proteolysis of a caspase-3/7 – specific
substrate and not caspase-3 – specific substrate. After cleavage by caspase the fluorescence of
AMC at 460 nm increases, while inhibitors of caspases prevent it. Compounds that showed
greater than 80% (~1% hit rate) inhibition were defined as hits and selected for re-validation and
further studies. Events defined as “multiplex hits” interfered with proteolytic activities of at least
two caspases. Bithionol was one of the three multiplex hits identified as capable of prominently
reducing the proteolysis of all three caspase substrates (Figs 3b and 4a–c). Since Bithionol was
identified by both cellular and biochemical multiplex screens (Fig. 3b), we further investigated
the efficacy of Bithionol and the breadth of its potential as a host-oriented, anti-pathogenic agent.
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Figure 4.4: Bithionol reduces pathogenicity of toxins by inhibiting host caspases

(a–c) Bithionol inhibits caspases. FRET data showing fluorescence emission from two reactions, where caspase-containing
cellular lysate cleaves fluorescently labeled substrate peptide without drugs, or in the presence of 33 µM Bithionol. FRET
substrates were specific for cleavage by caspase-3 (a), caspase-3/7 (b), and caspase-6 (c). (d–f) Bithionol was tested for its ability
to inhibit cytotoxicities mediated by toxins of cholera, diphtheria, and Pseudomonas. RAW264.7 cells were incubated with
indicated doses of Bithionol for 1 hour, followed by 12 hours intoxication with Pseudomonas and cholera toxins. Diphtheria toxin
was added to C32 cells for 24 hours. Cell viability was determined by MTT assay and is shown as the percentage of survivors
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relative to cells not treated with drugs. (g) Different concentrations of Bithionol are tested for their ability to inhibit caspase
activity in cellular lysate of cells. Cells were pre-treated with Pseudomonas aeruginosa exotoxin A to induce caspases. FRET
was done using substrates cleaved by caspases-3, -6, and -3/7. (i) Bithionol inhibits cytotoxicity mediated by P. aeruginosa
exotoxin A in sensitive human B-lymphocytes. B-cells were seeded at 1 × 104 cells/well on 96-well plates and were incubated
with indicated doses of Bithionol for 1 hour, and then challenged with the toxin for 6 hours. Cell viability was determined by
Alamar Blue assay and is shown as the percentage of survivors relative to cells not treated with drugs. (i) Bithionol inhibits
caspases-1, -3, -6, -7, and -9. Bithionol was tested at 33 µM for its ability to inhibit FRET reactions of purified human caspases-1
through 10. Percent inhibition values are shown, and compared to activity of caspases untreated with Bithionol. Phenogram of ten
human caspases, assembled by Multalin using Dayhoff alignment parameters, is used to demonstrate relative homology of
caspases.

Bithionol reduces the pathogenicity of a range of toxins by inhibiting host caspases
To investigate the potency of Bithionol, we first performed drug titration curves in host
RAW264.7 and C32 cells. We demonstrated that Bithionol was able to reduce diphtheria,
cholera, and Pseudomonas toxins-mediated cytotoxicities with an EC50 of 10 µM (Fig. 4d–f).
We tested the effect of different concentrations of Bithionol for the ability to inhibit the
proteolytic cleavage of substrates specific for cellular caspases-3, 6, and 3/7. We observed a
linear dose-dependent caspase-inhibitory efficacy of Bithionol, with an IC50 of 21, 13, and
11 µM for caspases-3, -6, and -3/7, respectively (Fig. 4g). These results are consistent with antitoxins EC50’s of Bithionol in cellular tests (Fig. 4d–f).
We also tested whether Bithionol reduces cellular sensitivity to PE in randomly selected
PE-sensitive HapMap cells. We observed that the drug protected three cell lines treated with
amounts of PE that are sufficient to kill 80% of cells (Fig. 4h). These results confirm the antitoxin potential of Bithionol in host cells.
Humans have 10 well-characterized caspases that collectively form a pathway, often
referred to as “the caspase cascade”, where caspases-3, -6, and -7 are the executioners of cell
death and are activated by other caspases [22]. We tested the ability of Bithionol to inhibit
activities of ten purified recombinant human caspase proteins, and we demonstrated that in
addition to caspases-3, -6, and -7, Bithionol inhibited activities of caspases-1 and -9, while
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having no inhibitory effects on other caspases (Fig. 4i). Together, these results demonstrate that
Bithionol is a direct inhibitor of a select subset of caspases, and that it reduces cellular sensitivity
to toxins by targeting at least five host caspases.

Bithionol inhibits cytotoxic activity of anthrax toxins
Anthrax toxins, the major virulence factors of the Bacillus anthracis bacterium, include
an exotoxin protein complex consisting of a protective antigen (PA) and lethal factor (LF) that
act collectively to damage host cells. PA binds to cellular receptors, while LF acts as a protease
cleaving cytoplasmic MAPKKs [23]. Three additional host proteases mediate entry and lethality
of anthrax toxin: furin, cathepsin-B, and caspase-1 [14,23,24].
To test the ability of Bithionol to neutralize cytotoxic activity of anthrax toxin, we
examined its effect on cell viability in LF-PA – treated RAW264.7 cells. While 80% of cells
used for these assays normally undergo cell death within 6 hours of exposure to anthrax toxin,
Bithionol provided substantial protection against LF-PA – mediated cell killing at 33 µM (Fig.
5a).
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Figure 4.5: Bithionol inhibits anthrax toxin lethality

(a) Bithionol was tested for its ability to inhibit anthrax toxin-mediated cytotoxicity. RAW264.7 cells were incubated with the
indicated doses of Bithionol for 1 hour, followed by 6 hours intoxication with anthrax toxin PA-LF. Cell viability was determined
by MTT assay and is shown as the percentage of survivors relative to cells not treated with drugs. (b) Bithionol inhibits LF-PA–
induced activity of cellular caspase-1. RAW264.7 cells were treated with LF-PA for 1 hour, and then treated either with 33 µM
Bithionol or DMSO for 1 hour prior to lysis and determination of caspase-1 activity. The activity of caspase-1 was measured by
FRET assay. (c) MAPKK2 immunoblotting showing that Bithionol does not block proteolysis of cellular MAPKKs by anthrax
LF toxin. While MAPKK2 was cleaved in LF-PA treated RAW264.7 cells, treatment with Bithionol did not affect this process.
RAW264.7 cells were incubated with Bithionol or DMSO for 1 hour before addition of vehicle control or 1 µg/ml PA + LF for up
to 60 minutes. Cells were lysed and analyzed via immunoblotting with a MAPKK2–specific antibody. Tubulin was used as a
loading control. (d,e) Bithionol reduces cell death induced by the hybrid toxin FP59, which has been widely used as an anthrax
LF surrogate and contains the PA binding site of LF, as well as a toxin domain derived from PE. Bithionol-treated cells were
found to be less sensitive to treatment with PA + FP59. PA was either in the native 83 kDa form (d), or used as 63 kDa–lacking
20 kDa Furin cleavage domain (e). RAW264.7 cells were preincubated with a titration of Bithionol for 1 hour, followed by a
6 hours intoxication with 0.5 µg/ml 83 kDa PA + FP59 or Furin processed 63 kDa PA + FP59. Cell viability was measured via
MTT. (f) Bithionol doesn’t inhibit cathepsin B protease activity in RAW264.7 cells. RAW264.7 cells were treated with 33 µM
Bithionol of DMSO for 1 hour prior to lysis, and determination of cathepsin B activity was assessed by FRET assay.
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Caspase-1 activation, which occurs in LF-PA intoxication, was monitored using a FRET
assay. While we observed an induction of caspase-1 activity upon LF-PA treatment in the
absence of Bithionol, caspase-1 induction was not detected in Bithionol-treated cells challenged
with anthrax toxin (Fig. 5b). This result confirms that Bithionol inhibits anthrax toxin
cytotoxicity by at least inhibiting caspase-1 activity.
We investigated whether additional anthrax toxin pathway proteases are inhibited by
Bithionol in live cells. By utilizing MAPKK immunobloting (Fig. 5c), a hybrid toxin FP59 [25]
that enters host cells by utilizing PA, but kills cells by LF-independent mechanism (Fig. 5d,e),
and cathepsin-B FRET assay (Fig. 5f), we demonstrated that Bithionol does not inhibit
proteolytic activities of cellular LF, furin, and cathepsin-B.

Bithionol inhibits ricin and Botulinum neurotoxin A - induced death in vitro and in vivo
Ricin is another toxin known to induce host caspases-3, -6, and -7 [15,20]. It reaches the
mammalian cytoplasm through the retrograde transport route from the plasma membrane to ER
via endosomes and the Golgi apparatus (Fig. 3a). Once in the cytoplasm, ricin inhibits cellular
protein synthesis by cleaving a glycosidic bond within the large rRNA of the 60S subunit of
eukaryotic ribosomes [4]. We tested the ability of Bithionol to reduce ricin - mediated cellular
killing and observed that the drug was able to reduce toxin-mediated cytotoxicity with an EC50
of 10 µM (Fig. 6a).
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Figure 4.6: Bitionol and other pathogenic agents

(a) Bithionol reduces ricin mediated cellular killing. Human K562 cells were incubated with indicated doses of Bithionol for
2 hours, and then challenged with ricin for 24 hours. Cell viability was determined by FSC/SSC flow cytometry. (b) Ten Swiss
Webster CFW mice were treated with 6 mg/kg Bithionol in the presence or absence of botulinum neurotoxin serotype A complex
(BoNT/A) by oral gavage. Animals were observed over 7 days. The Bithionol and BoNT/A survival curves are statistically
different based on the Log-rank (Mantel-Cox) test, P < 0.0001. (c) Bithionol does not inhibit proteolytic activity of BoNT/A.
FRET data showing fluorescence emission from two reactions, where 5 nM BoNT/A light chain cleaves fluorescently labeled
SNAP-25 substrate peptide without drugs or in the presence of 33 µM Bithionol. (d) The ability of Bithionol to inhibit Zika virus
(ZIKV) in host Vero E6 cells and astrocytes was measured by fluorescent microscopy. The virus-inhibitory EC50 concentrations
were determined.

Botulinum neurotoxin serotype A (BoNT/A) is a protease that translocates into the host
cytoplasm from acidic endosomes, where it cleaves the synaptosome-associated protein, SNAP25, and inhibits neurotransmitter release among neurons, leading to muscular paralysis [26].
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BoNT/A has been reported to cause cellular caspases-3 and -7 - dependent apoptosis [16].
After oral administration, Bithionol crosses the intestinal epithelium and is absorbed into
the bloodstream in humans and many animals [27]. We evaluated the efficacy of Bithionol as a
therapeutic agent during BoNT/A intoxication in Swiss Webster mice. Animals were given a
lethal oral dose of BoNT/A complex in the presence and absence of Bithionol. Ninety percent of
animals that received a lethal dose of BoNT/A without Bithionol died within 3 days of
intoxication (Fig. 6b). All mice that were challenged with BoNT/A and treated with Bithionol at
6.0 mg/kg, survived without displaying toxin-associated symptoms, such as wasp waist and
paralysis (Fig. 6b).
Since BoNT/A acts as a protease, we investigated whether Bithionol directly inhibits the
proteolytic activity of BoNT/A by utilizing a FRET assay. An optimized SNAP-25 peptide with
a fluorogenic FITC group at the N-terminus and DABCYL quenching group at the C-terminus
was used as the substrate [28]. After cleavage by BoNT/A the fluorescence of FITC at 523 nm
increases. We determined that Bithionol did not affect the proteolysis rate of the fluorescent
substrate (Fig. 6c). This result shows that Bithionol protects mice by inhibiting host targets,
rather than by inhibiting the toxin itself.

Bithionol acts as a Zika virus inhibitor
In addition to pathogenic toxins, viruses are also known to propagate by activating host
caspases and inducing programmed cell death [29]. Similarly to toxins, Zika virus (ZIKV) has
been reported to lead to cell-death by inducing host caspase-3 and neuronal apoptosis during its
propagation [30,31]. Moreover, caspases have previously been reported to cleave various viral
proteins, affect viral protein localization, promote viral genome replication and viral assembly,
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and have been reported to be necessary for viral replication and propagation [32,33].
Upon observing that Bithionol protects cells from caspase-inducing toxins, we
hypothesized that Bithionol might also be able to inhibit the pathogenicity of the Zika virus. The
strains utilized in this study were chosen to gauge the ability of Bithionol to inhibit Zika virus
strains found within both ZIKV lineages. Both strains utilized in this study had low passage
histories and had intact glycosylation sites. Furthermore, both strains were geographically and
genetically divergent. Puerto Rico Zika strain, PRVABC59, is closely related to virus strains
circulating in the New World including those strains isolated in Brazil and Guatemala. The
African ZIKV lineage is ancestral to the Asian lineage; as such Senegal strain, DAK AR D
41525, was selected as it is a low passage strain that is mycoplasma free. We tested Bithionol’s
ability to inhibit Senegal and Puerto Rico isolates of ZIKV in infected Vero E6 cells and human
astrocytes. To detect infected cells, immuno-staining was performed using anti-Flavi-virus
envelope protein antibodies. Bithionol inhibited the abundance of Puerto Rico ZIKV in Vero E6
cells with an EC50 of 6.7 µM as well as Senegal ZIKV in Vero E6 and human astrocytes with
EC50’s of 5.5 and 6.3 µM respectively (Fig. 6d and Table S1). These data indicate that Bithionol
is effective in inhibiting ZIKV in host cells.

Discussion
In order to discover the inhibitors of pathway hubs that mediate the lethality of multiple
bacterial toxins, we identified host caspases as hubs and focused the discovery process on
therapies that are able to inhibit caspases and reduce toxins’ cytotoxicities. Collectively,
utilization of both cellular- and biochemical-based multiplex drug screens provided us with i) a
drug hit (Bithionol), ii) a drug-target (caspases), and iii) an assessment of breadth of spectra of
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the drug. This disease-network-based approach utilizing two diverse multiplex drug screenings,
which we term “Disparate Dual Multiplexing”, could significantly shorten the time needed for
drug-discovery followed by target-identification steps in a historically lengthy process. In the
future, additional types of drug screens could be included in disparate multiplex-based drug
screens, such as genetic-based, and immunology-based screens, thus expanding our approach to
Disparate Triple, Disparate Quadruple (etc.) Multiplex drug screening.
Bithionol was previously approved to treat helminthes, and although the exact target
within these species is not known, it is believed that the drug inhibits oxidative phosphorylation
of parasites [34]. Our study has uncovered five additional Bithionol targets: caspases-1, -3, -6, 7,

and

-9,

which

by

definition

makes

Bithionol

a

polypharmacological

drug.

Polypharmacological phenomena include a single drug acting on multiple targets of either a
unique or multiple disease pathways. Just like in the current study, many of the
polypharmacological approaches aim to discover the unknown off targets for existing drugs, and
this approach is called “drug repurposing” [3,35]. Therefore, this raises the possibility that
Bithionol targets additional non-caspase host proteins exploited by toxins. To our knowledge, no
other drugs used in humans have been reported to inhibit caspases. In the future, Bithionol can be
investigated for its efficacy to treat other non-infectious human diseases caused by detrimental
activities of caspases, such as neurodegenerative diseases and inflammatory bowel disease.

Bithionol was replaced by the more effective anti-helminthic, Praziquantel [34].
Moreover, Bithionol was used as a bacteriostatic additive in cosmetic products, but was
discontinued in 1967 due to photosensitizing effects [27]. Presently, Bithionol is still used to
treat helminthic cases in some Asian and European countries and is included as an active
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ingredient in Fonergine®, used to treat mouth and throat disorders in Argentina [36]. The current
drug discovery and development process can take many years for the successful introduction of a
new drug into the market. Thus, the current de novo drug discovery and development paradigm
is ineffective for dealing with rapidly emerging biological threat agents. Under such
circumstances, drug repurposing may offer numerous advantages. Since Bithionol already has a
well-established safety and pharmacokinetic profiles in patients and animals, as well as bulk
manufacturing methods [27], the drug could rapidly be made available for a new indication if a
biological emergency was to occur. Most notably, it has been shown that after oral
administration of 50 mg/kg of Bithionol in humans, the drug reaches serum concentrations that
range from 225 to 480 µM [27], which is on average 30 times higher than the EC50 achieved by
our cellular tests (Figs 4,5, and 6). This suggests that it is possible to achieve effective anti-toxin
and anti-Zika Bithionol doses in blood by oral administration. In addition, Bithionol was i) used
to treat cerebral paragonimiasis [37] and is known to cross the brain-blood barrier [38]; ii)
reported to cross the placental barrier [39]; and iii) was used to treat paragonimiasis in a
population that included children and pregnant women [40]. All of these observations suggest
that Bithionol is likely to achieve anti-Zika efficacy in humans.

Methods
Chemicals and reagents
All bacterial toxins were purchased from List Biological Laboratories (Campbell, CA).
FP59 was a gift from Stephen Leppla (NIAID). Ricin was purchased from Vector Laboratories.
Clinical Compound Library (CCL) drug library was purchased from Johns Hopkins University
Bloomberg School of Public Health. Bithionol was repurchased from Sigma-Aldrich.
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Cell culture and cell lines
RAW264.7 mouse macrophage and human C32 melanoma cells (ATCC CRL-1585) were
maintained in DMEM (Sigma-Aldrich). Human B-lymphocytes were grown in IMDM
(Invitrogen). Human K562 chronic myelogenous leukemia cells (ATCC CCL-243) were grown
in RPMI 1640 Medium (Invitrogen). Vero E6 (ATCC CRL-1586) were maintained in MEM
(Corning). Primary human Astrocytes (NHA-Astrocytes-AGM, Lonza, #CC-2565) were cultured
in Astrocyte Basal Medium (Clonetics ABM, Lonza) supplemented with AGM SingleQuot Kit
Supplement and Growth factors (CC-4123). All media were supplemented with FBS, penicillin,
and streptomycin.

Human B-lymphocytes sensitivity to Pseudomonas toxin-mediated lethality
Human B lymphocytes were treated with serial dilutions of P. aeruginosa exotoxin A for
48 hours. The viability of B cells was determined by Alamar Blue (AbD Serotec, BioRad)
fluorescence, as described by the manufacturer. Each data point shown in Fig. 2a represents the
average and SD of results from three wells. Cell viability is shown as the percentage of survivors
obtained relative to cells in the absence of the toxin (100% survival). LD20 was calculated for
each cell line. Statistical analysis and graphical presentation were performed using GraphPad
Prism software. A P value <0.05 was considered statistically significant. Homozygous medians
were compared by an unpaired t test. CHB and JPT, two East Asian populations, were pooled in
order to obtain a more accurate estimate of effect size in the larger combined population.
Because linear regression is sensitive to outliers, we removed one outlier in CHB, as the log
sensitivity of this cell line couldn’t be determined within the toxin range tested.
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Cellular drug screens
RAW264.7 cells (10,000 per well) were seeded in 96-well plates 24 hours before the
assay. Cells were treated with compounds for 1 hour, and then challenged with either 2 µg/ml PE
or 4 µg/ml cholera toxin for 12 hours. As rodent cells are insensitive to diphtheria toxin, C32
cells were treated with 2 µg/ml of diphtheria toxins for 24 hours. Determination of RAW264.7
and C32 viability was performed by MTT assay. Cell viability is defined as the percentage of
surviving cells obtained relative to cells treated with DMSO (100% survival).

Caspases FRET drug tests
Caspases were induced in RAW264.7 by treating cells with 2 µg/ml of PE for 4 hours.
Caspases were extracted and their activity was measured using Caspase Assay Kit (SigmaAldrich) with or without drugs.
The FRET reaction was performed in 96 well plates, and each reaction contained 16 µM
substrate peptides (Peptides International) conjugated with a 7-amino-4-methylcoumarin group
at the N-terminus and acetyl group at the C-terminus. The amino acid sequences of substrates
were: DNLD for caspase-3, DQTD for caspases-3 and -7, and VEID for caspase-6. CCL
compounds were tested at the final concentration of 33 µM, as pilot testing indicated that CCL
screen at 16 µM would not yield a sufficient number of multiplex hits. Reactions were initiated
by adding caspase – containing lysate to a final concentration of 6 µg/ml. Kinetic measurements
were obtained at 37 °C every 5 minutes for 2 hours using a fluorescent plate reader. Excitation
and emission wavelengths were 360 nm and 460 nm, respectively, with a cutoff wavelength of
365 nm. Rates of reactions were quantified by the Microsoft Excel LINEST function. A
BioVision kit was used to test Bithionol’s ability to inhibit FRET reactions of purified
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recombinant human caspases-1 through 10. One unit of caspase was used in a single FRET
reaction.

Toxins treatments and cell viability assays
Cells (10,000 per well) were seeded in 96-well plates 24 hours before the assay. Cells
were treated with Bithionol for 1 hour. RAW264.7 cells were challenged with anthrax toxins that
include LF or FP59 and PA83 or PA63 (for 6 hours), PE (for 12 hours), or cholera toxin (for
12 hours) at 0.5, 2, and 4 µg/ml respectively. C32 cells were treated with 2 µg/ml of diphtheria
toxin for 24 hours. Determination of cells viability was performed by MTT assay. Blymphocytes cells were seeded in a 96-well plates at 10,000 cells/well 1 hour before toxin
treatment, treated with Bithionol for 1 hour, and then challenged with 8 µg/ml PE for 6 hours.
Determination of lymphocyte viability was determined by Alamar Blue (AbD Serotec, BioRad)
fluorescence, as described by the manufacturer. Each data point shown for MTT and Alamar
Blue assays indicates the mean ± SD value obtained in triplicate assays done in a representative
experiment. At least three such experiments were carried out.

MAPKK2 cleavage assay
N-terminal MAPKK2, anti-tubulin, and anti-PA antibodies were purchased from Santa
Cruz Biotechnology. RAW264.7 cells were pre-treated with 33 µM of Bithionol for 1 hour.
Following pre-treatment, the cells were exposed to 0.5 µg/ml of PA and LF at 37 °C for up to
three hours in the presence of 33 µM of Bithionol. The cells were then washed with cold PBS
five times and lysed with RIPA buffer containing a protease inhibitor mixture (Santa Cruz
Biotechnology, Inc.). Cell lysates were quantified using the BCA protein quantification kit
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(Pierce) and loaded onto 4–12% denaturing gels (Criterion XT Precast Gel, Bio-Rad). After
electrophoresis for several hours, the gel was transferred overnight to nitrocellulose membranes;
membranes were probed with anti-MAPKK2 or anti tubulin antibodies. Quantitative Western
blot analyses of the bands were accomplished using the Odyssey infrared imaging system (LICOR Biosciences).

Cellular cathepsin B and caspase-1 activity assays
Cathepsin B and caspase-1 activities in total cell lysates were determined using an
InnoZyme cathepsin B activity assay kit (EMD Millipore) and caspase activity assay kit
(BioVision), performed according to the manufacturers’ instructions. Cellular cathepsin B or
caspase-1 activities with and without Bithionol were tested by pre-treating cells with 33 µM of
Bithionol for 1 hour, followed by lysing cells and testing protease activities with fluorescently
labeled specific substrates. Caspase-1 activities were induced by 1 hour pretreatment of cells
with 0.5 µg/ml of LF + PA, and was compared to cells un-induced by the toxin. Fluorescence
intensities indicating cathepsin B or caspase-1 activities were measured (Molecular Devices,
Spectra Max 384 PLUS).

Ricin treatment and cell viability assay
K562 cells were seeded at a density of 2 × 105 cells/well in 24-well plates. Cells were
pre-treated with Bithionol for 2 hours and 0.4 ng/ml ricin was added to the treated wells.
Following the 24-hour ricin treatment, the percent of viable cells (within the live gate by
FSC/SSC) was measured by flow cytometry using a BD Accuri C6 Flow Cytometer. Experiment
was performed in duplicate for each condition.
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Mice intoxication studies
10 Swiss Webster (CFW) mice (6 weeks old) were treated with 0.125 mg/mouse
Bithionol in the presence or absence of BoNT/A complex (3 µg/mouse, Metabiologics, Madison
WI) in phosphate gelatin buffer (0.028 M sodium phosphate pH 7.0, 0.2% gelatin) by oral
gavage. Animals were observed over a period of 7 days. Methods were carried out in accordance
with approved guidelines. All experiments were performed in accordance with relevant
guidelines and regulations. All animal experiments have been approved by the Western Regional
Research Center IACUC. Euthanasia protocols follow recommendations established by the
American Medical Veterinary Association Guideline for Euthanasia to minimize animal pain and
suffering.

BoNT/A light chain FRET assay
The reaction volume was 250 µl per well in 96 wells plate, containing 50 mM HEPES pH
7.4 containing 0.05% TWEEN 20, 5 µM SNAPtide (BoNT/A substrate peptide) conjugated with
DABCYL and FITC (List Biological Laboratories, Inc), and 33 µM of Bithionol. Reactions were
initiated by adding BoNT/A light chain to a final concentration of 5 nM. Kinetic measurements
were obtained at 37 °C every 1 min for 50 min using a fluorescent plate reader. Excitation and
emission wavelengths were 490 nm and 523 nm, respectively, with a cutoff wavelength of
495 nm. At least three such FRET experiments were carried out.
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Zika virus high content imaging infections assay
We utilized strains from both ZIKV lineages (African and Asian) to assess the potential
for Bithionol to inhibit viral abundance. ZIKV strain DAK AR D 41525 was originally isolated
from a pool of Aedes africanus mosquitoes in Senegal in 1984 (passage history: AP61#1,
C6/36#1, Vero 3) and strain PRVABC59 was originally isolated from human sera in Puerto Rico
in 2015 (passage history: Vero 6). Cells were pre-treated with Bithionol for 2 hours prior to
infection. Vero E6 cells were exposed to ZIKV at an MOI of 0.5; astrocytes were infected with
ZIKV at an MOI of 15. Infection was terminated after 48 hours by fixing samples in formalin
solution. For visualization of Zika infection cells were treated for 1 hour with anti-Flavi-virus
envelop protein monoclonal antibody 4G2, followed by anti-mouse IgG conjugated with
Dylight488 (Thermo). Cells were stained with Hoechst (Life Technologies) for nuclei staining
and with Cell Mask Red (Life technologies) for cytoplasm staining. Nuclei were stained with
Draq5 (Biostatus) diluted in PBS buffer. Images were acquired on the Opera imaging plate
reader (Perkin Elmer) and analyzed using Harmony and Acapella PE software. A detailed
protocol is described in the supplemental file.
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Transition
The previous chapter describes our first attempt at multiplex screening. In
these studies we screened drugs for their ability to inhibit caspases in FRET
screens, as well as toxin-challenge cell survival assays against Pseudomonas
exotoxin A, Cholera toxin, and Diphtheria toxin (all cause an increase in cellular
caspases). Our one drug hit that was successful in all screens is Bithionol.
Multiplex screening allowed us to more accurately indentify an HPEP as well as to
identify a broad-spectrum therapy. As a proof of Bithinol’s ability to inhibit
caspases, we were able to show that Bitionol could be successful in toxin
challenges against Botulinum toxin as well as being capable of reducing Zika virus
in cellular studies. The following chapter will describe an attempt to identify single
drugs that could be HPEPs and anti-pathogen simultaneously on account of the
observation that anthrax toxins and the host proteins that anthrax toxin exploit are
both proteases, with the hopes to create a more effective anti-anthrax therapy.
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Chapter 5

Cross-inhibition of pathogenic agents and the host proteins they exploit

Leeor Zilbermintz, William Leonardi, Sharon H. Tran, Josue Zozaya, Alyssa Mathew-Joseph,
Spencer Liem, Anastasia Levitin, and Mikhail Martchenko
Abstract
The major limitations of pathogen-directed therapies are the emergence of drugresistance and their narrow spectrum of coverage. A recently applied approach directs therapies
against host proteins exploited by pathogens in order to circumvent these limitations. However,
host-oriented drugs leave the pathogens unaffected and may result in continued pathogen
dissemination. In this study we aimed to discover drugs that could simultaneously cross-inhibit
pathogenic agents, as well as the host proteins that mediate their lethality. We observed that
many pathogenic and host-assisting proteins belong to the same functional class. In doing so we
targeted a protease component of anthrax toxin as well as host proteases exploited by this toxin.
We identified two approved drugs, ascorbic acid 6-palmitate and salmon sperm protamine, that
effectively inhibited anthrax cytotoxic protease and demonstrated that they also block proteolytic
activities of host furin, cathepsin B, and caspases that mediate toxin’s lethality in cells. We
demonstrated that these drugs are broad-spectrum and reduce cellular sensitivity to other
bacterial toxins that require the same host proteases. This approach should be generally
applicable to the discovery of simultaneous pathogen and host-targeting inhibitors of many
additional pathogenic agents.
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Introduction
The traditional method of treating most human diseases is to direct a therapy against
targets in the host patient, whereas conventional therapies against infectious diseases are directed
against the pathogen. Unfortunately, the efficacy of pathogen-oriented therapies and their ability
to combat emerging threats such as genetically engineered and non-traditional pathogens and
toxins have been limited by the occurrence of mutations that render pathogen targets resistant to
countermeasures. Thus, host proteins exploited by pathogens are potential targets for therapies
[1].
Host proteins and pathways exploited by Bacillus anthracis toxins are well understood
[2]. B. anthracis causes anthrax infections and leads to toxemia in humans and animals,
rendering antibiotic therapies ineffective in the later stages of infection. The major virulence
factors of the bacterium include an exotoxin protein complex consisting of protective antigen
(PA) and lethal factor (LF), which act collectively to damage the host [2]. Proteases play
important roles in anthrax toxin mediated host-cell killing. PA binds to host cellular receptors in
the native form of 83 kDa (PA83) ]3,4], and once bound, host protease furin cleaves a 20 kDa
fragment from the N-terminus of PA, thus activating the PA protein of 63 kDa (PA63) [5].
Following activation, PA forms a heptamer and binds LF6. The toxin undergoes clathrin-type
endocytosis, mediated by another set of host proteases, calpains and cathepsin B7,8. A decrease
in endosomal pH induces the formation of an endosomal membrane PA channel, by which LF
translocates into the cytosol9.
Once in the cytosol, LF itself acts as a protease that cleaves and inactivates host mitogenactivated protein kinase kinases (MAPKK) 1–4, 6, and 710. The MAPKK cleavage event
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prevents the passage of signals in the ERK1/2, p38, and c-Jun N-terminal kinase pathways10,11,
which mediate responses to a variety of cellular stresses. In addition, rat NLRP1 and mouse
NLRP1b proteins can also be directly cleaved by LF at sites near their N termini11,12. The
cleavage of host proteins by LF results in the activation of the inflammasomes, resulting in rapid
macrophage cell death mediated by additional host proteases, caspases-1 and -311,12.
While the discovery of LF inhibitors has focused on new chemical compounds that either
inhibit its protease activity or its cytoplasmic entry (reviewed in13), repurposing of existing
drugs that simultaneously inhibit LF and the host proteases that assist LF, offers potential
advantages. We used a fluorescence resonance energy transfer (FRET) assay, where LF cleaves a
MAPKK2 peptide, to screen and identify approved drugs that affect the rate of the proteolytic
reaction. We identified chemical and peptidic compounds that effectively inhibited cleavage of
MAPKK2 peptide, as well as host furin, calpain, cathepsin B, and caspases. Two of those
chemicals, ascorbic acid 6-palmitate and salmon sperm protamine, suppressed LF-induced cell
death, as well as the cytotoxicity induced by cholera toxin and Pseudomonas aeruginosa
exotoxin A. This study offers new solutions to treat these infectious diseases by using drugs that
cross-inhibit pathogen and host targets.

Results
Observation of functional similarities between pathogenic agents and the host proteins exploited
by them
Cytotoxic bacterial and plant toxins have evolved to exploit host proteins and cellular
pathways that mediate the entry of those toxins into host cells and induce cell-death pathways.
We observed a widespread phenomenon of structural or functional similarity between pathogenic
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proteins of bacteria, viruses, fungi, or other parasites and the host proteins that are exploited by
them (Table 1). For example, similarities were reported for proteases of anthrax [7,8,14,15] and
botulinum toxins [16,17], as well as HIV-1 [18,19,20,21] and Hepatitis C [22,23,24] proteases
and endocytosis-mediating host proteases. Furthermore, shiga glycosidase H toxin exploits host
glycosidase H [25]; Candida albicans cell wall adhesins bind to structurally similar host
cadherins during fungal invasion [26]; and Streptokinase and Staphylokinase exploit host
plasminogen activators kinases [27,28]. A drug screen against multiple proteins within the same
pathway is possible if these proteins are similar in function or structure. Therefore, finding
therapies that cross-inhibit multiple proteins within a single pathway is of great interest.
Table 5.1: The observation that many pathogenic and host proteins they exploit belong to the same
functional class.
Pathogenic
agent
Anthrax Lethal
Toxin
Botulinum
neurotoxins
Candida albicans
Als3
Hepatitis C NS23 and NS3-4
HIV-1 PR
Pasteurella
Multocida toxin
Plasmodium
berghei ALAS
and FR
Shiga toxin
Staphylokinase
and
Streptokinase

Exploited host
protein
Furin, calpain,
cathepsin B, caspase1, caspase-3
caspase-3/7

Shared function

References

Proteases

7,8,14,15

Proteases

16,17

E-cadherin and Ncadherin
Furin, calpain,
caspase-3
Furin, calpain,
cathepsin B, caspase1/3
A2B Adenosine
Receptor
ALAS-1 and FECH

Adhesins

26

Proteases

22, 23, 24

Proteases

18, 19, 20,
21

Adenosine
deaminases
Hemebiosynthesis

45

Endoglycosidase H
Plasminogen
activators (PLAT and
PLAU)

Glycosidases
Kinases

25
27,28

46

In an effort to identify existing drugs that might be repurposed as novel cross-inhibitors
of pathogenic agents and the host proteins exploited by them, we screened the Johns Hopkins
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Clinical Compound Library (JHCCL) of chemicals [29]. We looked for compounds capable of i)
inhibiting the proteolytic activities of Bacillus anthracis lethal toxin and the host proteases
exploited by it (Fig. 1a) in biochemical FRET assays (Fig. 1d), and ii) reducing cytotoxicities of
B. anthracis lethal toxin, Cholera toxin, and Pseudomonas aeruginosa exotoxin A (Fig. 1c).
These toxins were chosen for this study because their pathways of entry into host cells are well
understood [30], making these toxins good tools for identification of broad-spectrum drugs.
Figure 5.1: The use of the Johns Hopkins Clinical Compound Library (JHCCL) to screen for
inhibitors of anthrax lethal toxin and host proteases

(a) Schematic depiction of host protease components within the pathway that mediates the delivery of anthrax toxin into
cytoplasm. Lethal factor (LF) interact with a second B. anthracis protein, protective antigen (PA), whose role is to bind to host
cell receptors, CMG2 and TEM8. Three host cell proteins furin, calpain, and cathepsin B mediate the endocytosis of the toxin
complex. Once in the cytoplasm, LF cleaves host MAPKK’s and NLRP1, and initiates apoptosis through induction of proteolytic
activity of host caspases-1 and -3. (b,c) Overall approach scheme: JHCCL is screened by biochemical FRET assay looking for
drugs that are able to reduce proteolytic activities of anthrax toxin and five host proteases that mediate toxin lethality. (b)
Schematic diagram of FRET screen to identify drugs that inhibit proteolytic reaction of LF, (c) followed by FRET reactions to
test the ability of LF inhibitors to also inhibit proteolytic reactions mediated by host furin, calpain, cathepsin B, caspase-1, and
caspase-3. In addition, LF FRET inhibitors are tested for their ability to reduce LF-PA cytotoxicity of mouse macrophage cells.
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A biochemical screen for JHCCL drugs that cross-inhibit proteolytic activities of anthrax toxin
and host proteases that mediate its lethality
In our initial screen we searched for the drugs that were capable of simultaneously
inhibiting the proteolytic activities of anthrax LF as well as of host proteases that mediate the
toxin’s lethality in cell-free FRET assays. To screen and identify drugs that inhibit LF proteolytic
activity we utilized a fluorescence-based FRET assay. An optimized MAPKK2 peptide with a
fluorogenic FITC group at the N terminus and DABCYL quenching group at the C terminus was
used as the LF substrate. After cleavage by LF the fluorescence of FITC at 523 nm increases,
while a known inhibitor of LF, surfen hydrate [31], prevents it from cleaving the substrate and
producing fluorescence (Fig. 1b). We screened 1,585 previously approved drugs for their ability
to reduce the rate of the LF proteolytic reaction. Surfen hydrate is not included in JHCCL
because is it not used clinically. Compounds that showed greater than 66% (~1% hit rate)
inhibition when tested at 33 µM were selected for re-validation and further studies. We
discovered ten compounds that effectively inhibited LF in the FRET assay, nine of which were
chemical molecules and one which was a 33 amino acid long peptide called salmon sperm
protamine (Table 2). Of the ten chemical hits, six drugs were structurally similar to each other
and contained carbon chains of at least 12 carbons (Table 2). These drugs are cetylpyridinium
bromide, domiphen bromide, cetalkonium chloride, sodium lauryl sulfate, ascorbic acid 6palmitate, and sodium dodecylbenzenesulfonate. Three other small molecule drugs, docusate
sodium, thyropropic acid, candesartan cilexetil, successfully inhibited the LF proteolytic reaction
and were of various structures (Table 2). Moreover, one of the drugs that successfully inhibited
the LF FRET reaction was a peptide, salmon sperm protamine. We determined that the IC50
values for the LF FRET reaction of these ten drugs were in the high nM to low µM range (Table
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2), with cetalkonium chloride showing the lowest IC50 of 160 nM, while arginine-rich salmon
protamine displaying the lowest potency of 18 µM.
Table 5.2: The potencies of ten JHCCL drugs for inhibition of anthrax LF, as well as human
proteases exploited by it (furin, caspase, cathepsin B (Cath B), caspase-1 (Casp 1), and caspase-3
(Casp 3)) in biochemical FRET assays.

Conditions where no FRET inhibition is observed denoted as N/I.

We tested several truncated versions of salmon protamine and showed that while the N’
terminal region of the peptide (amino acids 1–10) lost the anti-LF and anti-furin FRET
efficacies, and the C’ terminal (amino acids 23–33) showed potency similar to the full length
protamine, the central portion of protamine (amino acids 11–22) displayed improved anti-LF
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activity (Table 3). Additionally we observed that a truncated version of protamine that contains
the N’ terminal and central portions of protamine showed an even further improvement of
protamine anti-toxin efficacy of just 1 µM. A truncated version of protamine that contains the
central and C’ terminal regions of protamine demonstrated anti-LF efficacy that is comparable to
the full-length protamine.
Table 5.3: The potencies of truncated versions of salmon sperm protamine and full-length human
protamines in LF and furin FRET assays are shown. N/I stands for no inhibition
Peptide Name
(amino acids)

Peptides amino acid
sequences

LF
IC50 µM

Furin

18 ± 0.01

Percent
Inhibition
with
33 µM of
drug
LF
107 ± 1.4

Salmon Sperm
Protamine (1-33)
Salmon Sperm
Protamine (1-10)
Salmon Sperm
Protamine (1122)
Salmon Sperm
Protamine (2333)
Salmon Sperm
Protamine (1-22)
Salmon Sperm
Protamine (1133)
Human Sperm
Protamine (1-51)

MPRRRRSSSRPVRRRRR
PRVSRRRRRRGGRRRR
MPRRRRSSSR

298 ± 0.01

28 ± 1.0

N/I

PVRRRRRPRVSR

5 ± 0.13

95 ± 0.1

84 ± 33

RRRRRGGRRRR

15 ± 0.01

93 ± 2.4

150 ± 5.3

MPRRRRSSSRPVRRRRR
PRVSR
PVRRRRRPRVSRRRRRR
GGRRRR

1 ± 0.04

98 ± 0.6

91 ± 1.8

10 ± 0.04

99 ± 0.2

86 ± 1.2

MARYRCCRSQSRSRYY
RQRQRSRRRRRRSCQT
RRRAMRCCRPRYRPRC
RRH

14 ± 0.32

88 ± 1.2

97 ± 1.7

96 ± 1.2

We observed that arginine-rich human sperm protamine exhibited an anti-LF FRET IC50
comparable to that of salmon protamine (Tables 3 and 4). We tested several truncated versions of
human protamine and showed that while the N’ terminal region of the peptide (amino acids 1–
17) showed a decreased anti-LF FRET efficacy, central (amino acids 18–34) and C’ terminal
(amino acids 35–51) regions showed potency similar to the full length human protamine (Table
4).
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Table 5.4: The potency of full length and truncated versions of human protamine in LF FRET
assay
Peptide
Name (amino
acids)

Peptides amino acid sequences

LF
IC50
µM

Percent
Inhibition
with
33 µM of
drug
LF
88 ± 1.2

Human Sperm
Protamine (151)
Human Sperm
Protamine (117)
Human Sperm
Protamine
(18-34)
Human Sperm
Protamine
(35-51)

MARYRCCRSQSRSRYYRQRQRSRRR
RRRSCQTRRRAMRCCRPRYRPRCRR
H
MARYRCCRSQSRSRYYR

14 ±
0.32
67 ±
0.01

37 ± 0.7

QRQRSRRRRRRSCQTRR

24 ±
0.15

72 ± 2.1

RAMRCCRPRYRPRCRRH

28 ±
0.03

55 ± 0.9

All ten LF-inhibitors were also tested for their ability to inhibit proteolytic FRET
reactions of host furin, calpain, cathepsin B, caspase-1, and caspase-3, all of which mediate LF
cytotoxicity (Fig. 1c). With the exception of caspase-1, all human proteases were effectively
inhibited by several LF inhibitors (Table 2). The only drug that exclusively inhibited LF was
domiphen bromide. None of the drugs inhibited all proteases.

Ascorbic acid 6-palmitate and salmon sperm protamine inhibit cytotoxic activity of anthrax
toxins
In order to test the ability of LF inhibitors to neutralize the cytotoxic activity of anthrax
toxin (Fig. 1c), we examined the effect of ten JHCCL hits on cell viability in LF-PA treated
mouse macrophage RAW264.7 cells. Between 80 and 90 percent of cells used for these assays
normally undergo cell death within 3 hours of exposure to anthrax lethal toxin under the
experimental conditions employed. Ascorbic acid 6-palmitate and salmon sperm protamine were
the only two drugs that provided complete protection against LF-PA mediated cell killing (Fig.
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2a). In contrast, the remaining eight compounds failed to protect cells against LF-PA mediated
cellular killing due to their cytotoxicity in RAW264.7 cells. These experiments indicate that
ascorbic acid 6-palmitate and salmon sperm protamine display target-specific biological activity
and are therefore candidates for further development into broad-spectrum therapeutics.

Figure 5.2: Ascorbic acid 6-palmitate and salmon sperm protamine act as broad-spectrum antitoxins

(a) Ascorbic acid 6-palmitate and salmon sperm protamine were tested for their ability to inhibit LF-PA83-mediated cytotoxicity.
RAW264.7 cells were seeded at 1 × 104 cells/well on 96-well plates and the following day were incubated with indicated doses
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of drugs for 1 hour, followed by 3 hours intoxication with 0.5 µg/ml PA83 + LF. (b) Sixteen µM of salmon sperm protamine
reduces cellular sensitivity to LF + PA63. RAW264.7 cells were pretreated either with DMSO or with protamine for 1 hour, and
then treated with 0.5 µg/ml of LF and PA63 for 6 hours. Averages, standard deviations, and P values are shown for each
condition. (c,d) Ascorbic acid 6-palmitate and salmon sperm protamine were tested for their ability to inhibit cytotoxicities
mediated by Pseudomonas aeruginosa exotoxin A and Cholera toxin. RAW264.7 cells were seeded at 1 × 104 cells/well on 96well plates and the following day were incubated with indicated doses of drugs for 1 hour, followed by 12 hours intoxication with
2 and 4 µg/ml of Pseudomonas (c) and Cholera (d) toxins respectively. Cell viability was determined by MTT assay (Materials
and Methods) and is shown as the percentage of survivors relative to cells not treated with drugs. Averages, standard deviations,
and P values are shown for each condition. Each P value represents a comparison of drug-treatment condition to a condition
without drugs.

Poly-arginine peptides were previously shown to simultaneously inhibit furin and lethal
factor in biochemical and cellular assays [32,33]. We tested the ability of arginine-rich protamine
to reduce the cell death induced by LF and PA in the 63 kDa form - lacking the 20 kDa furin
cleavage domain (Fig. 2b). Fifty percent of cells used for these assays normally undergo cell
death within 6 hours of exposure to LF-PA63 under the experimental conditions employed. We
observed that protamine effectively protected all cells when used at 16 µM, compared to cells
treated with LF-PA63 in the absence of drugs (P < 0.0001). Since this form of PA bypasses the
need for furin protease cleavage, this data argues that protamine reduces toxin-mediated cell
death by inhibiting LF directly.

Ascorbic acid 6-palmitate and salmon sperm protamine act as broad-spectrum anti-toxins
It has been previously shown that Pseudomonas aeruginosa exotoxin A (PE) and Cholera
toxin exploit several host proteins for their binding and entry into host cells and initiate
programmed cell death by inducing activities of host caspase-3 [34,35]. To test the ability of
ascorbic acid 6-palmitate and salmon sperm protamine to neutralize cytotoxic activity of the two
toxins, we examined their effects on cell viability in toxin-treated RAW264.7 cells. While 50%
and 70% of cells used for these assays normally undergo cell death within 6 hours of exposure to
CT and PE respectively, ascorbic acid 6-palmitate and salmon sperm protamine provided
substantial protection against PE and CT-mediated cell killing at 16 µM compared to cells treated
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with toxins in the absence of drugs (P < 0.0001) (Fig. 2c,d).
Discussion
This study identified drugs that simultaneously target pathogenic factors and host
proteins exploited by them. This approach is based on the observation that some virulence
proteins and host proteins they utilize, belong to the same functional class. However, this
approach has possible limitations such as potentially low efficacy of drugs, or if a pathogenic
factor exploits multiple redundant host proteins, some of which could be functionally unrelated
to the toxin. Moreover, host protein inhibiting therapies may cause side effects, and this is a
possible explanation as to why many drugs that were shown to have potency in biochemical
FRET assays were cytotoxic in cellular anti-toxin assays (Fig. 2). Some of the drugs that caused
the cytotoxicity display structural properties that resemble detergents, while other drugs could be
cross-reacting with essential host proteins.
Detergents are compounds comprised of a hydrophobic hydrocarbon tail and a
hydrophilic charged headgroup. When dissolved in water at a given concentration, detergent
molecules will form micelles, with the hydrophobic tail in the interior of the micelle and the
headgroup at the exterior. The minimal detergent concentration at which micelles are observed at
a specific temperature is called “Critical Micelle Concentration” (CMC). It is known that at or
above the CMC, detergents cooperatively bind to most proteins, which thereafter undergo
denaturing rearrangements of their protein structures. Micelles act as detergents with the
hydrophobic core of the micelle binding to the hydrophobic regions of proteins. It is also known
that at submicellar concentrations, detergents may bind to specific binding sites of several
proteins [36,37]. For example, the CMC of one of our FRET hits, sodium lauryl sulfate, a
molecule commonly known as SDS, is 8 mM [38]. In our study the IC50 of SDS was found to be
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2.9 µM, four orders of magnitude of concentrations below the CMC. Similarly, the IC50 of
ascorbic acid 6-palmitate in our study is 0.4 µM, while its CMC is 0.8 mM [39], four orders of
magnitude difference. Therefore, since all of our detergent-like molecules displayed potencies
well below their respective CMC’s, we believe that their interaction with the studied protein
targets is specific. The data shown in Table 2 argues that these drugs are selective in their
inhibition of targets, and none of the drugs inhibited all targets indiscriminately. Lastly, with the
exception of ascorbic acid 6-palmitate, all detergent-like molecules discovered in this study
belong to the common ionic category of detergents, as their headgroups bear a charge. In
contrast, ascorbic acid 6-palmitate is a non-ionic molecule, and this class of detergent-like
molecules are known to less likely act as detergents.
Protamines are arginine-rich peptides that package DNA into chromatin in vertebrate
sperm. It is thought that the N’ terminus of protamine is unstructured, contains a lesser number
of arginine residues, and bends back and over the central arginine-rich portion of protamine
before binding the DNA [40]. There could be several reasons why the N’ termini of salmon and
human protamines are less potent than their full-length equivalents. The N’ termini of protamines
contain the lowest number of arginines, which could be necessary for inhibiting LF protease
activity. We hypothesize that in addition to arginine numbers, the secondary structure of
protamine is also important, as protamine constructs that include the N’ terminal and central
portions are the most potent anti-LF peptides.
The anti-toxin efficacies of drugs in cellular assays were observed to be lower than the
efficacies seen in FRET assays, possibly because some of the host protein targets are
intracellular, and drugs are required to cross cell membrane barrier. Moreover, the experimental
timing used to determine drugs’ inhibitory activity on proteases in FRET assays is very different
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from the timing used to measure the ability of drugs to block toxins in cellular assays. Cellular
assays are done by pre-incubating cells with drugs for 1 hour, following by 6–24 hours of toxin
treatments, depending on the kind toxin used. In contrast, FRET reactions were performed for up
to 2 hours without drug pre-incubation. Finally, one protease activity unit of a single protease
was used per FRET reaction. In contrast, the number of protease activity units per one cell is not
known and may not be the same used in FRET assays.
The pharmacokinetics and safety of both identified drugs are well characterized. Ascorbic
acid 6-palmitate is fat-soluble form of vitamin C formed from ascorbic acid and palmitic acid. It
is used as a source of vitamin C as well as an antioxidant food additive (E number E304), which
is approved for use as a food additive in the EU, the U.S., Australia, and New Zealand [41].
Salmon sperm protamine is used as an antidote for heparin overdoses [42]. In addition,
protamine is used to slow down the onset and increase the duration of insulin action [43].
Numerous screens for LF inhibitors have been attempted in the past decade, however,
none of the identified hits have been approved for use in humans because of the long and
rigorous process of drug discovery and development. The current drug discovery and
development process can take 8 to 12 years for the successful introduction of a new drug into the
market [44]. Thus, the current de novo drug discovery and development paradigm is ineffective
for dealing with rapidly emerging biological threat agents. Drug repurposing may offer
numerous advantages under these circumstances. Since currently approved drugs already have
well-established safety and pharmacokinetic profiles in patients as well as bulk manufacturing
and distribution networks, they could rapidly be made available for a new indication if a
biological emergency were to occur.
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Methods
Chemicals and Reagents
All bacterial toxins were purchased from List Biological Laboratories (Campbell, CA,
USA). An FDA-approved drug library comprising of 1,585 drugs was purchased from Johns
Hopkins University Bloomberg School of Public Health, titled, Johns Hopkins Clinical
Compound Library (JHCCL). The drugs in the library were kept at −20 °C as 3.3 mM stock
solutions in sealed microtiter plates and were made using DMSO as solvent. Compounds of
interest were repurchased and reproduced from 3.3 mM solutions. Salmon sperm protamine,
cetylpyridinium bromide, domiphen bromide, cetalkonium chloride, sodium lauryl sulfate,
ascorbic acid 6-palmitate, sodium dodecylbenzenesulfonate, docusate sodium, and candesartan
cilexetil were purchased from Sigma-Aldrich (St. Louis, MO, USA). Thyropropic acid was
purchased from Toronto Research Chemicals Inc (Toronto, Ontario, Canada). All drugs were
prepared at 3.3 mM using DMSO as a solvent. Full-length human and truncated salmon and
human protamines were synthesized by LifeTein (Hillsborough, NJ, USA). All chemicals and
peptides in this study had purities greater than 98%.

LF FRET Drug Screen and Data Analysis
For screening JHCCL drugs in 96-well plates, the reaction volume was 250 µl per well,
containing 20 mM HEPES pH 7.2, 5 µM MAPKKide conjugated with DABCYL and FITC (List
Biological Laboratories, Inc), and 33 µM of JHCCL compound. Reactions were initiated by
adding anthrax LF to a final concentration of 6 µg/ml. Kinetic measurements were obtained at
37 °C every 40 sec for 50 min using a fluorescent plate reader. Excitation and emission
wavelengths were 490 nm and 523 nm, respectively, with a cutoff wavelength of 495 nm. A
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known LF inhibitor, surfen hydrate [31], was included as a control. Rates of reactions were
quantified by the Microsoft Excel LINEST function. Drugs that inhibited at least 66% of FRET
reaction at 33 µM were re-tested at decreasing concentrations in order to determine IC50.

Host Proteases FRET Tests
Drug hits that inhibited at least 66% of LF FRET reaction were also tested for their
ability to inhibit FRET reactions of human furin (New England Biolabs), calpain 1 (BioVision),
cathepsin B (EMD Millipore), and caspases-1 and -3 (BioVision). The fluorescently labelled
substrate peptide for furin FRET assay was purchased from Peptides International. The positive
control furin Inhibitor I was purchased from EMD Millipore. The calpain Inhibitor 1, ALLN,
was purchased from BioVision and used as a control. Amodiaquine (Sigma-Aldrich) was used as
a control inhibitor of cathepsin B. The universal caspase inhibitor Z-VAD-FMK (BioVision) was
used as a control. Rates of reactions were quantified by the Microsoft Excel LINEST function.

Cell Culture, Toxins Treatments, and Cell Viability Assays
RAW264.7 mouse macrophage cells were maintained in DMEM (Invitrogen)
supplemented with 10% FBS (Corning) and 100 µg/ml penicillin and streptomycin. RAW264.7
cells (10,000 per well) were seeded in 96-well plates (100 µl/well) 24 hours before the assay.
Cells were treated with drug hits for 1 hour at 37 °C 5% CO2. RAW264.7 cells were challenged
with anthrax toxins that include LF and native 83 kDa PA (for 3 hours), LF and PA in the 63 kDa
form (for 6 hours), P. aeruginosa exotoxin A (for 12 hours), or Cholera toxin (for 12 hours),
which were also pre-treated with identical drug concentrations, such that the final toxins
concentrations were 0.5, 0.5, 2.0, and 4.0 µg/ml respectively. Determination of RAW264.7
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viability was performed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay was performed as described1. Cell viability is defined as the percentage of surviving cells
obtained relative to cells treated with DMSO (100%). At least three such experiments were
carried

out.

Statistical

analysis

was

performed

using

GraphPad

Prism

software

(http://www.graphpad.com/scientific-software/prism/). Each P value represents a comparison of
drug-treatment condition to a condition without drugs, and values < 0.05 were considered
statistically significant.
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Concluding Remarks
The host proteins involved in the anthrax toxin internalization targets have proven to
be potential broad-spectrum therapies against other pathogenic agents that utilize those same host
proteins. We started off using a method that utilized similar yet disparate toxins, then moved on
to a multiplexing methodology, and finally we identified a drug that simultaneously interferes
with LF as well as host proteins that are exploited by LF to gain entry into host cells. In the
future more multiplex drug screening will be done for other pathogens and pathogenic agents
that span different protein families. In addition to cellular and FRET based assays we will
incorporate other screens, such as genetic and immunology-based screens. Using previously
approved drugs such as those in the John Hopkins Clinical Compound Library could shorten the
historically expensive and timely drug development process, due to the known pharmacokinetics
and pharmacodynamics of those drugs. In addition a benefit of repurposing those drugs could
mean that there exists manufacturing and distribution networks, this giving patients quicker
access to those therapies.
Amodiaquine, a previously approved antimalarial, is currently being tested in the
hopes that it could become a complimentary therapy for anthrax in addition to the commonly
prescribed antibiotics. Therapies for Anthrax and other deadly diseases fall under the FDA’s
“Animal efficacy rule,” whereby safety and efficacy must be shown in two animal models. In
addition, phase I clinical trials for humans must be completed, with any further trials in humans
being unethical for obvious reasons. Plans are underway to test Amodiaquine as an anthrax
antitoxin in rabbits and macaques. If Amodiaquine gets FDA approved, it could become the first
in a new class of host-oriented drugs, anti-pathogen therapies.
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